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In the existing literature, invasive direct vagus nerve stimulation (VNS) using high 
frequencies has shown to be effective in modulating the activity of the olfactory bulb in 
animal models. Under indirect vagus nerve stimulation, stimulation via peripheral nerves 
(such as median nerve stimulation-MNS) using low frequencies alleviates nausea, which 
indicates a potential contribution of the olfactory system. However, there is no research 
that assessed the effects of median nerve stimulation (either high- or low frequency) or 
high frequencies VNS on olfactory function in humans. The present study aimed to, 
therefore test the potential effects of non-invasive, direct and indirect stimulation of the 
vagus nerve (VN), using high- and low frequencies in humans.  
 
Two separate experiments were performed. In the first experiment, healthy adult male 
participants (n = 20) performed an odour threshold test (OTT), before and after receiving 
either, high-, low frequency MNS (indirect VNS) or placebo. Data from olfactory tests 
were analysed using paired parametric and non-parametric statistical tests (dependent on 
the presence or absence of normal distribution in the normality test using Shapiro-Wilk 
correction). Stimulation of the median nerve (MN) (indirect VNS) through high or low 
frequencies displayed no improvements in the performance of the OTT in healthy, adult 
male participants.  
 
The second experiment explored the effects of non-invasive, direct VNS through the 
auricular branch of the vagus nerve (AbVN). Healthy, adult male participants (n = 18) 
performed an OTT and supra-threshold test (STT), before and after receiving either, high-
, low frequency VNS or placebo. Supplementary exploration of bilateral orbitofrontal 
cortex (OFC) was performed using near-infrared spectroscopy (NIRS). NIRS data of 
separate stimulation parameters were statistically analysed using repeated-measures 
ANOVA across all stages of the experiment. Data from the olfactory tests were analysed 
using paired parametric and non-parametric statistical tests. Only direct auricular VNS 
under high frequency stimulation displayed improvements in olfactory function of the 
healthy participants in the STT (p:0.021, Wilcoxon sign-ranked test), with significant 
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differences in the NIRS recordings of the right hemispheric, OFC (p:0.014, post-hoc test 
with Bonferroni correction).  
 
Overall, the results of the present study demonstrated that non-invasive auricular VNS 
using high frequency stimulation can improve STT performance in healthy humans for 
the first time in the existing literature. Findings from this study provide important insights 
into the potential effects of high frequency VNS over the olfactory function via the OFC. 
Further studies are needed to investigate the entire network of olfactory system that 
responds to high frequency VNS. In addition, the results of the present study also 
underline a potential beneficial effect of high frequency VNS on early progression of 
olfactory impairments in Alzheimer’s and Parkinson’s disease, which, in this context, 


















I would like to first and foremost thank both of my supervisors, Dr. Yusuf Cakmak and 
Dr. Mei Peng. Both of you have been tremendously generous with your availability and 
feedback towards helping me with the experiments and the thesis write-up. For these 
reasons, I am forever grateful. Thank you for providing me an opportunity to work 
beside you both and learn about the immense research available on neuromodulation 
and olfactory function. I would also like to thank you both for helping me write my first 
article. This was much bigger feat than I could have anticipated and I could not have 
done it without your continued support, feedback and contributions. 
 
I would also like to thank my family. Mum and dad, thank you for being very 
supportive, and encouraging me to always aim a little higher that what I intend on 
initially. Thank you to my brother, Aaron for providing endless off-topic conversations 
and fixing my laptop when it decided to stop functioning. Without you guys, I could not 
have made it as far as I have and I will always be thankful for that. 
 
I would also like to thank all my friends, unfortunately listing you all and respective 
contributions would add numerous pages onto this section. But I cannot thank all of you 
enough for your support. If it wasn’t for your encouragement and support, I could be 
stuck at a stepping stone much further away from what I wanted, in terms of happiness 
or academia. Special shout outs to Will (for reading my draft thesis!), D and Juju, Josh, 
Mel, Myles, Rob, Beth, Mads, Jo-Jo and Ashley. I would also like to thank all the 
participants in the experiments for taking time off your busy schedules to be 
participants. Without you guys, I would potentially still be conducting the experiments 
now! 
 
For the staff, I would like to thank Eunice for your help for the first experiment. Thank 
you for helping me set up and perform the experiment when you were very busy in your 
Honours year. I would like to thank the Anatomy staff, Annette, Sally-Ann, Dot, Aven 
and Julia for your aid and support around the department. Thank you to Marion for 
sharing the lab space, your support around the second experiment was crucial for me to 
iv 
 
finish in a timely manner. Thanks to Sarah from Food Sciences for offering me advice 
and aid in the field of odours. I would like to thank the rest of the Anatomy staff for 
your support around the department and I would also like to thank the University of 
Otago for providing me the opportunity to further my knowledge in Science and 
























Table of Contents 
Abstract ....................................................................................................................................................................... i 
Acknowledgements ............................................................................................................................................. iii 
Table of Contents ................................................................................................................................................... v 
List of Tables ........................................................................................................................................................ viii 
List of Figures ........................................................................................................................................................ ix 
List of Abbreviations ............................................................................................................................................ x 
1.0 Introduction  ................................................................................................................................................... 1 
1.1 General Introduction ............................................................................................................................... 1 
1.2 Duality of the olfactory system anatomy ........................................................................................ 3 
1.2.1 Projection of odour signals to the primary and secondary olfactory regions of 
the cortex ........................................................................................................................................................ 5 
1.2.2 Orbitofrontal cortex, the ‘processor-hub’ of olfactory information in the cortex . 6 
1.2.3 Functions of the olfactory system ............................................................................................. 7 
1.2.4 Assessing olfactory function ........................................................................................................ 9 
1.3 Olfactory dysfunction in ageing and neurodegenerative diseases .................................... 11 
1.3.1 Ageing ................................................................................................................................................. 11 
1.3.2 Alzheimer’s disease ....................................................................................................................... 11 
1.3.3 Parkinson’s Disease ....................................................................................................................... 13 
1.4 Stimulation techniques of the vagus nerve and background of olfactory system 
modulation studies ........................................................................................................................................ 15 
1.4.1 Use of indirect, non-invasive vagus nerve modulation through the median nerve
 ........................................................................................................................................................................... 16 
1.4.2 Use of direct, non-invasive auricular stimulation of the vagus nerve ...................... 19 
1.5 Exploration of the olfactory network using near-infrared spectroscopy ....................... 24 
1.5.1 History of near-infrared spectroscopy .................................................................................. 24 
1.5.2 Use of near-infrared spectroscopy in conjunction with olfactory testing .............. 25 
1.6 Present aims and objectives ............................................................................................................... 26 
2.0 Methods ........................................................................................................................................................... 27 
2.1 Experiment 1: Use of median nerve stimulation (indirect vagus nerve stimulation) to 
modulate olfactory function ...................................................................................................................... 27 
2.1.1 Participants....................................................................................................................................... 27 
2.1.2 Procedure .......................................................................................................................................... 27 
2.1.3 Application of median nerve stimulation ............................................................................. 29 
2.1.4 Data analysis .................................................................................................................................... 30 
2.2 Experiment 2: Use of non-invasive, direct auricular vagus nerve stimulation to 
modulate olfactory functions .................................................................................................................... 31 
2.2.1 Participants....................................................................................................................................... 31 
2.2.2 Procedure .......................................................................................................................................... 31 
vi 
 
2.2.3 Application of non-invasive, direct auricular vagus nerve stimulation .................. 32 
2.2.4 Data analysis .................................................................................................................................... 34 
2.3 Information on the functional olfactory tests and near-infrared spectroscopy ........... 35 
2.3.1 Odour threshold test – Experiment 1 & 2 ............................................................................. 35 
2.3.2 Supra-threshold test – Experiment 2 ...................................................................................... 36 
2.3.3 University of Pennsylvania Smell Identification Test – Odour Identification Test 
– Experiments 1 & 2 ................................................................................................................................... 36 
2.3.4 Odour Discrimination/Memory Test – Experiments 1 & 2 ............................................ 37 
2.3.5 Near-infrared spectroscopy - Experiment 2 ........................................................................ 37 
3.0 Results .............................................................................................................................................................. 40 
3.1 Preliminary pre-screening olfactory test results ...................................................................... 40 
3.2 Experiment 1: Use of MNS (indirect stimulation of the vagus nerve) to modulate 
olfactory function ........................................................................................................................................... 40 
3.2.1 Odour threshold test results ...................................................................................................... 40 
3.2.2 Intergroup data from the odour threshold test ................................................................. 41 
3.3 Experiment 2: Use of non-invasive, direct auricular vagus nerve stimulation to 
modulate olfactory functions .................................................................................................................... 43 
3.3.1 Odour threshold test results ...................................................................................................... 43 
3.3.2 3-Stage odour threshold test - near-infrared spectroscopy results (Pre-S OTT, 
stimulation, Post-S OTT) ........................................................................................................................ 43 
3.3.3 Results of supra-threshold test ................................................................................................ 43 
3.3.4 3-Stage supra-threshold test – near-infrared spectroscopy (Pre-S STT, 
stimulation, Post-S STT) ......................................................................................................................... 44 
3.3.5 All stages (5-stage) near-infrared spectroscopy analysis (Pre-S OTT, Pre-S STT, 
stimulation, Post-S OTT, Post-S STT) ................................................................................................ 44 
3.3.6 Intergroup data from the odour threshold test and supra-threshold test, and 
respective near-infrared spectroscopy recordings from the orbitofrontal cortex ........ 50 
4.0 Discussion ....................................................................................................................................................... 51 
4.1 Main findings ............................................................................................................................................ 51 
4.2 Present results in conjunction with existing literature on direct and indirect vagus 
nerve stimulation ........................................................................................................................................... 52 
4.3 Exploration of neuroanatomy underlying direct vagus nerve stimulation .................... 55 
4.4 Median nerve and its potential connections with the olfactory networks ..................... 57 
4.4 Exploration of the primary communication centre of the olfactory cortex 
(orbitofrontal cortex) using near-infrared spectroscopy during olfactory function ......... 61 
4.5 Clinical implications of VN neuromodulation ............................................................................. 63 
4.6 Future studies on direct or indirect VN neuromodulation ................................................... 65 
4.7 Conclusion ................................................................................................................................................. 69 
References ............................................................................................................................................................. 70 
Appendix 1 ............................................................................................................................................................. 89 
vii 
 
Appendix 2 ............................................................................................................................................................. 90 

































List of Tables 
 
 
Table 3.1 Results from the pre-screening OIT and ODMT from Experiment 1 and Experiment 2.
 ..................................................................................................................................................... 41 
Table 3.2. Pre-stimulation OTT result analysis (Experiment 1). ................................................ 42 





















List of Figures 
 
Figure 1.1. The location of primary and secondary olfactory areas of the MOS in the 
human brain. ..................................................................................................................... 4 
Figure 1.2. The pathway of the main and accessory olfactory system. ............................ 7 
Figure 1.3. Distribution patterns of AD pathology (amyloid deposits). ......................... 13 
Figure 1.4. The Braak stages of PD pathology. .............................................................. 14 
Figure 1.5. Displays the trajectory of the MN through the forearm and hand. .............. 17 
Figure 1.6. Anatomy of the external ear, including innervation zones of cranial and 
spinal nerves and electrode placement regions of Experiment 2.................................... 21 
Figure 2.1. Schematic sequence of each stage of the Experiment 1 (non-invasive, MNS-
indirect stimulation of the VN). ...................................................................................... 29 
Figure 2.2. Location and set-up of the non-invasive MNS (indirect VNS) (Experiment 
1). .................................................................................................................................... 30 
Figure 2.3. Schematic sequence of each stage of the Experiment 2 (non-invasive, direct 
auricular VNS). ............................................................................................................... 33 
Figure 2.4. Set-up of the NIRS. ...................................................................................... 39 
Figure 3.1 A-C. OTT results (Experiment 1). ................................................................ 42 
Figure 3.2. OTT and OTT - NIRS recording from the OFC (Experiment 2). ................ 45 
Figure 3.3. STT and STT- NIRS recording from the OFC (Experiment 2). .................. 46 
Figure 3.4. STT and STT - NIRS recording from the right hemisphere of the OFC using 
direct high frequency VNS (Experiment 2). ................................................................... 47 
Figure 3.5. STT and STT - NIRS recording from the right hemisphere of the OFC using 
direct low frequency VNS (Experiment 2). .................................................................... 48 
Figure 3.6. STT and STT - NIRS recording from the right hemisphere of the OFC under 
placebo condition (Experiment 2). ................................................................................. 49 
Figure 4.1. The pathway of auricular VN to the olfactory centres. ................................ 57 








List of Abbreviations 
 
Abbreviation First Page Display Full Extension 
AbVN Page i Auricular branch of the Vagus 
Nerve 
AD Page 2 Alzheimer’s Disease 
ANZCTR Page 28 Australian New Zealand Clinical 
Trials Registry 
AOB Page 4 Accessory Olfactory Bulb 
AOS Page 3 Accessory Olfactory System 
DMV Page 1 Dorsal Nucleus of Vagus 
EA- Page 19 Electroacupuncture 
EC Page 4 Entorhinal Cortex 
EEG Page 26 Electroencephalography 
fMRI Page 25 functional Magnetic Resonance 
Imaging 
HbO2 Page 26 Oxygen Haemoglobin 
LC Page 59 Locus Coeruleus 
LN Page 14 Lewy Neurites 
MN Page i Median Nerve 
MNS Page i Median Nerve Stimulation 
MOB Page 4 Main Olfactory Bulb 
MOS Page 2 Main Olfactory System 
NIRS Page i Near-infrared Spectroscopy 
NPvt Page 59 Paraventricular thalamic nucleus 
NTS Page 1 Nucleus Tractus Solitarius 
OB Page 1 Olfactory Bulb 
ODMT Page 9 Odour Discrimination/Memory 
Test 
ODT Page 9 Odour Discrimination Test 
OFC Page i Orbitofrontal Cortex 
OIT Page 9 Odour Identification Test 
OM Page 9 Odour Memory Test 
ORT Page 9 Odour Recognition Test 
xi 
 
OT Page 4 Olfactory Tubercle 
OTT Page i Odour Threshold Test 
PC Page 4 Piriform Cortex 
PC-6 Page 17 Pericardium acupuncture point-6 
PD Page 2 Parkinson’s Disease 
PET Page 7 Positron Emission Tomography 
Ppm Page 37 parts per million 
PVN Page 58 Paraventricular Nucleus 
rSO2 Page 26 Regional haemoglobin oxygen 
saturation 
rVLM Page 61 rostral ventrolateral medulla 
RN Page 58 Raphe Nucleus 
S-I Page 17 Primary Somatosensory Cortex 
S-II Page 17 Secondary Somatosensory 
Cortex 
SMA Page 17 Supplementary Motor Area 
STT Page i Supra-Threshold Test 
TENS Page 19 Transcutaneous Electrical Nerve 
Stimulation 
UPSIT Page 9 University of Pennsylvania 
Smell Identification Test 
VN Page i Vagus Nerve 
VNS Page i Vagus Nerve Stimulation 
VNO Page 4 Vomeronasal Organ 











1.1 General Introduction 
 
In existing literature, use of direct VNS has demonstrated the ability to modulate the 
function of olfactory bulb (OB) in animal models (1). So far, the investigation of 
common nerves in their ability to alter the function of the olfactory system includes the 
olfactory, trigeminal, facial and glossopharyngeal nerves (2–8). However, no studies 
have yet tested non-invasive, direct or indirect stimulation of the VN as a potential 
neuromodulatory technique on olfactory functions. Neuromodulation of the VN was 
initially performed to treat epilepsy through an invasive, transcutaneous stimulation (9). 
Neuromodulation of the VN can follow a direct method, using invasive and non-
invasive approaches, or an indirect method, using a non-invasive approach via the 
peripheral nerve stimulation (in the context of this thesis, MNS).  
 
Previous studies using electrostimulation on the MN resulted in significant 
improvements on gastric mobility and alleviating symptoms of nausea and vomiting in 
both animal models (10–14) and human studies (13,15,16). This effect was understood 
to occur via VN brainstem nuclei including Nucleus Tractus Solitarius (NTS) and 
Dorsal Nucleus of Vagus (DMV) (14,17–19),. Previous literature has indicated that 
there is a role of gastric distension in the modulation of the OB in animal models (20–
22). This could potentially underlie the effects of MNS on the activity of the OB (using 
VN neuronal network as an indirect pathway). Analogous to the indirect VNS 
techniques (through MNS), the use of direct VNS under high frequencies has also 
demonstrated an increase in the activity of the OB in animal studies (1). However, 
previous studies in human subjects have only explored the use of direct VNS under low 
frequencies as it fit the stimulation parameters for the conditions of the patients that 
were used in these studies (8,23).  
 
                                                          
a Work from this thesis has been published as a manuscript by Frontiers in Neuroscience (244). 
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Part of the main olfactory system (MOS), the OB play a key role in processing smell, in 
addition to several primary and secondary olfactory structures of this olfactory system 
in the cerebral cortex (24–28). Part of the secondary olfactory structures in the cortex, 
the OFC is considered the relay station of olfactory connections (29,30). The OFC has 
displayed increased activation in response to odour stimulus in neuroimaging 
techniques (NIRS) (31–33). Olfactory impairments are not only prevalent with ageing 
(34,35) but also in various neurodegenerative diseases such as Alzheimer’s disease 
(AD) or Parkinson’s disease (PD) (34,36–38). Both of the aforementioned 
neurodegenerative diseases present olfactory impairments from the earliest stages and 
therefore implores investigation into potential treatment options. In light of these 
potential benefits, this study focused on effects of different neuromodulatory techniques 
on olfactory function in the MOS. 
 
The introductory chapters outline the relevant background information to the current 
thesis. First, a brief exploration on the anatomy and pathways of the olfactory networks 
is examined. The importance of olfactory function, alongside olfactory tests and 
subsequent olfactory dysfunction present in ageing and neurodegenerative diseases is 
detailed next. After the review on olfactory function, investigation of direct (auricular 
VNS) and indirect (through the stimulation of the MN) stimulation of the VN in current 
literature in addition to the neuromodulatory effects associated with these nerves is 











1.2 Duality of the olfactory system anatomy 
 
The role of the olfactory system is pivotal, in our interactions with the surrounding 
environment. This includes perceiving odours or detecting pheromones that play an 
important role in human social interactions (34,39,40). The olfactory system is our most 
primitive sense, yet is a sensory modality in which human beings exhibit plasticity 
throughout our entire lifetime. The mechanisms of neuronal plasticity in the olfactory 
system have been investigated at both cellular and cognitive levels (41–43). The 
importance of olfactory systems is highlighted through several neurodegenerative 
diseases that present early impairments in olfactory functions (mentioned in chapter 
1.3.2 and 1.3.3) (34,36,38). 
 
It is understood in the existing literature that vertebrate mammals use two distinctive 
olfactory systems: the MOS (Figure 1.1) and the accessory olfactory system (AOS) 
(44–47). Although evidence is scarce in the existing literature that these two systems 
present a dichotomy of olfactory function, it is understood that the AOS processes 
pheromones while the MOS is associated with processing general odorants (44–46). A 
previous hypothesis has been proposed that the AOS is responsible for processing large, 
high-weight molecules that are not volatile in the air. In comparison, the MOS processes 
low-weight molecules, which become airborne and contact the olfactory epithelium 
(47). The separation in function of the two olfactory systems could also be associated 
with their structural localisations. Vomeronasal sensory neurons (part of the AOS) are 
understood to be located in an enclosed tubular structure, where there is a restriction to 
the access of air-borne odorants. In comparison, the MOS sensory neurons are located 
on nasal turbinates’ that are readily exposed to volatile odorants (44). 
 
The AOS comprises of the vomeronasal organ (VNO) and the accessory olfactory bulb 
(AOB). VNO is located at the base of the nasal septum while the AOB is located at the 
dorsal-caudal surface of the main olfactory bulb (MOB). In these regions, the 
vomeronasal receptor axons connect with the centrifugal afferents from the nuclei of the 
AOS. The AOS helps control of neuroendocrine function and social behaviour (through 
processing of chemical compounds-pheromones). VNO, using bipolar neurons, project 
to the AOB, which processes vomeronasal input. Additionally, the AOB projects to the 
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amygdala (Figure 1.2), the bed nucleus of the stria terminalis and posteromedial cortical 




Figure 1.1 The location of primary and secondary olfactory areas of the main 
olfactory system in the human brain. 
Labelled in the figure, primarily olfactory areas which include the piriform cortex (PC), 
entorhinal cortex (EC), parrahippocampal gyrus, olfactory tubercle (OT). The secondary 
olfactory areas that are labelled include the OFC, hippocampus, thalamus and 
hypothalamus. Image obtained and approved by the W.D. Trotter Anatomy Museum 
(Department of Anatomy, University of Otago, New Zealand), edited with labels of the 
primary and secondary olfactory areas. 
 
 
The second olfactory system is the MOS. In the context of this thesis, discussions of the 
olfactory system will be in reference to the MOS. The MOS can be divided into primary 
olfactory areas [PC, OT, amygdala (periamgydaloid cortex) and EC] and secondary 
olfactory areas (OFC, hippocampus, hypothalamus and thalamus) (Figures 1 and 2) 
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(26,27,48). The PC and EC are two key regions of the primary olfactory areas of the 
MOS. The PC is interchangeably referred to as the primary olfactory cortex as it 
receives the majority of inputs from the OB. The PC is also the largest central olfactory 
areas, spanning the anatomical junction between the frontal and temporal lobe (referred 
to in two subdivisions-frontal piriform and temporal piriform cortex). The EC is 
considered the gateway for information leaving and entering the hippocampal formation 
and a key component of the medial temporal lobe memory system. This structure is one 
of the main terminals of the PC (34) and plays a large role in intrinsic memory functions 
such as maintaining stimulus-specific neural activity (working memory). This is 
suggested to be a crucial feedback pathway that is impaired (along with the PC) in 
neurodegenerative olfactory deficits (49). 
 
 
1.2.1 Projection of odour signals to the primary and secondary olfactory 
regions of the cortex 
 
Olfactory structures involved in processing odours are presented in Figures 1.1-1.2. In a 
short summary, perceived odorants reach the olfactory cleft and are passed through the 
mucus layer by the olfactory binding proteins. The olfactory epithelium is only located 
in the superior portion of the nasal cavity. Therefore, the majority of inspired air around 
and down the nasal pathways cannot reach the olfactory binding proteins. This could 
potentially work as a selective process where only odorants that are sniffed or drawn in, 
are processed through the olfactory system (39). These odorants bind onto the olfactory 
receptor neuron’s cilia, each of, which have receptors that are specialised for a precise 
number of odours (50). Detailed in an article by Kovacs (26), peripheral bipolar 
receptor cells, numbering at millions per nose, are located in the olfactory epithelium of 
the nasal cavity. The axons of the olfactory neurons branch to the superficial layer 
(olfactory nerve layer) and synapse onto the glomerular layer of the OB.  
 
The OB is the first communication structure responsible for processing smell. This 
structure hosts an intricate and complex internal circuitry, which is reviewed in an 
article by Arruda & colleagues (24). In summary, there are two types of 
excitatory/output neurons (mitral and tufted cells) and inhibitory interneurons 
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(periglomerular and granule cells). The cell bodies and dendrites of these neurons are 
organised in separate layers, which contributes to their unique olfactory functions (24). 
The olfactory nerve fibres connect to the mitral and tufted cells of the OB. It travels 
initially to the primary olfactory cortex (PC) and then, to the primary olfactory areas 
through the use of the olfactory tract and the OT (51,52). The olfactory information 
from the primary olfactory areas is then projected to the secondary olfactory areas 
(OFC, hippocampus, hypothalamus, thalamus) (26,27,48).  
 
 
1.2.2 Orbitofrontal cortex, the ‘processor-hub’ of olfactory information in 
the cortex 
 
The OFC is a crucial component of the MOS, operating as the main neocortical 
projection site for numerous olfactory regions in the cortex. This structure sends 
reciprocal feedback to the PC and EC, in addition to the primary and secondary 
olfactory areas (29,30). The OFC is located at the ventral surface of the prefrontal 
cortex and receives information from the taste, olfactory and somatosensory inputs (53). 
Although considered a part of the secondary olfactory cortex, this structure receives 
somatosensory inputs from the frontal and pericentral operculum, insular cortices, 
amygdala, mediodorsal nucleus of the thalamus and pars magnocellularis. The OFC also 
projects to regions of the temporal lobes that includes inferior temporal cortex, cingulate 
cortex, preoptic region, lateral hypothalamus (ventral tegmental area) and head of 
caudate nucleus (29,53). 
 
The OFC is responsible for a diverse range of olfactory function. This structure is one 
of the primary areas in the cerebral cortex that represents smell (in addition to 
processing reward values of smell). The OFC is also associated with processing rapid 
reversal of behaviour by stimulus-reinforcement association re-learning), executive 
behaviours and represents positive affective aspects of somatosensory stimuli (27,29). 
Using positron emission tomography (PET), current literature has reported that 
perception, discrimination and recognition of odours all involve the orbitofrontal, 
cingulate and insular cortices (52). Separate functional imaging studies also reported an 
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increase in bilateral OFC activation (in comparison to the temporal, parietal or occipital 




Figure 1.2. The pathway of the main and accessory olfactory system.  
Pathways of the MOS are presented using blue arrows, with light-blue arrows for the 
primary olfactory areas, while the darker-blue/black arrows represented projections into 
the secondary olfactory areas of the cortex. The red arrows indicate the AOS. Retrieved 
from Kandel (54). 
 
 
1.2.3 Functions of the olfactory system 
 
Humans are thought to have a sense of smell that is inferior to other animals due to the 
decline in olfactory-gene numbers (55,56). However, this decline is compensated by a 
greater capacity to analyse complex smell signals due to the enlarged cortical centres  
(55,56). Even within the human population, there is a large variability in our ability to 
detect odours. There are some populations expressing the ability to detect several 
hundred odours while other populations express the capacity to detect several thousand 
odours (55).The first indication on how humans detect an odour came from Dr. L. Buck 
and Dr. R. Axel in 2004. They identified 350 different odorant receptors in the cell 
membranes of human olfactory receptor neurons and found that stimulating different 
patterns of olfactory receptor proteins (single or combination of specific odorant 
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receptors), were perceived as ‘unique’ odours in the brain (57). The olfactory receptors 
in the nose are very sensitive, capable of picking up faint odours. Our olfactory system 
also allows a rapid adaptation of olfactory sensations if there is prolonged presence of 
the same odorant. This is due to the inhibition of action potentials by specialised granule 
cells in the OB and by fatigue of odorant receptor function caused by ongoing, similar 
odour presentation (57).  
 
Our ability to detect and perceive odours determines our preference to specific foods, 
which in turn, can have substantial impact on our health and our risk of developing 
chronic conditions such as obesity or diabetes (55). The olfactory system allows us to 
detect spoiled food or airborne toxins in our surrounding environment (34,39,55,58). 
The olfactory system can also have an influence in the kinematics of hand shaping (the 
reach to grasp movement). In an article by Bult & colleagues (59), the reach to grasp 
movement was indicated to be influenced by the presentation of odours. Specifically, it 
was indicated that the motor plan evoked by the odours were very fine-grained, to the 
extent that it could affect the pattern of angular excursion at the level of individual 
fingers’ joints and degrees of synergic movement amongst digits (59).  
 
Our olfactory system can also contribute towards mating preferences. In a study by 
Wedekind & colleagues (60), a group of women were asked to rate the shirts worn by 
men (for two nights avoiding anything that could alter their ‘natural’ odour) under three 
criteria (intensity, pleasantness and sexiness). The results from the study indicated that 
women preferred T-shirts worn by men with different compatibility genes. This 
suggested that humans could potentially, in a subconscious manner, use smell to pick 
partners who present different compatibility genes that could be associated with a 







1.2.4 Assessing olfactory function 
 
There are two different types of olfactory processes when it comes to perception of 
odours. Orthonasal process, which occurs when odour molecules are delivered to the 
olfactory epithelium through the nares. The second is retronasal process, which occurs 
when odorant molecules from the oral cavity are delivered through the nasopharynx and 
posterior choanae to the olfactory epithelium in the olfactory cleft (61–63). Olfactory 
function can be assessed from different aspects with various tasks available. These 
include odour identification test (OIT- the subject is required to identify the name of a 
presented odour), odour discrimination test (ODT- a target odour is presented along 
with distinct odours and the subject must distinguish, which one is the target odour), 
odour memory test (OMT- the use of time delays between target odour presentation and 
the response of the subject for the target odour), OTT (the test of the minimal intensity 
that the subject can detect), odour recognition test (ORT- the test that requires the 
subject to recognise the name or substance of the presented odorant and STT (the test 
that assesses the subject’s perception to odorants above threshold) (64,65).  
 
There are several techniques available for investigating chemosensory function (e.g. 
several tasks mentioned in the previous paragraph). Suitable methods to access 
population-based olfactory assessment must involve a valid and sensitive measure that 
enables quantification of sensation and comparison across individuals. These methods 
should also provide a protocol that is a rapid, reliable, convenient, cost-effective and 
user-friendly. Currently, two techniques are commonly used for clinical studies.  
 
University of Pennsylvania Smell Identification Test (UPSIT-OIT) and odour 
discrimination/memory tests (ODMT) provides a reliable measure, with a test-retest 
reliability above 0.90 (66). These tests also correlate more closely to clinical setting 
than traditional measures of olfaction (66). Previous literature has indicated that UPSIT 
tests enables the analysis reflective of central olfactory processing, but not of peripheral 
aspects of olfactory function (which can be measured through the OTT) (29). As an 
alternate method, the Sniffin’ Sticks technique has been used frequently in past 
literature to observe measures of OTT (65,67–73). In the OTT, a measure of repeatedly 
ascending and descending concentrations of the same odorant is tested using the 
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Sniffin’ Sticks technique. This enables the identification of the least detectable 
concentration for a particular odour (29). Quantitative olfactory testing methods such as 
UPSIT-OIT/ODMT or Sniffin’ Sticks all involve orthonasal processing.   
 
Using the Sniffin’ Sticks method, an article by Hedner & colleagues (74) proposed the 
idea that cognitive variables for different types of olfactory tests could be associated 
with separate areas of the cortex. Specifically, they indicated that performance in the 
OTT could be driven by sections of the cortex that are responsible for low-order 
perceptual functions (volume of the OB related to the peripheral sensory input of 
olfactory processes). In comparison, performances in ODT, OIT, STT or tests of 
hedonic value of odours poses more cognitive demands and are represented in cortical 
areas that are responsible for higher-order olfactory function (74). Several studies have 
also concluded that the processes of OTT differentiate from other olfactory tests that 
require more cognitive processes including ODT, OIT, ORT, OMT and STT (70,73–
76).  
 
Initial methods of evaluating STT in odour perception began with the use of category 
rating scales. These methods were direct and allowed the measures of perceptual 
differences between subjects and in only a theoretical manner, explored the absolute 
strength of sensations. However, doubts were raised whether they could produce 
effective results across all sensory modalities (77) because the category scales are not 
spaced to give scale ratio properties (i.e. a rating of 6 on the scale is not twice as that of 
rating of 3). Instead, subjects were forced to assign sensations to categories that 
correspond to constant perceptual intervals with no true zero value, with the resulting 
data lying outside a ratio continuum (78–80).   
 
An alternative method to access STT is to use varying odour intensities of the same 
odour and observe if participants can identify the target odours (81). This methodology 
avoids the issues associated with the use of category rating scales mentioned previously. 
It is understood in the existing literature that STT functions are an important element of 
the olfactory system and STT results do not show correspondence with other olfactory 
measures, especially the OTT (82,83). Therefore, this thesis examined olfactory 
11 
 
performance with both OTT-representing low-order olfactory function and STT-
representing higher-order olfactory function (74). 
 
 





About half of the elderly population between the ages of 65 to 80 years present 
olfactory impairments (64,84,85). Olfactory impairments are present in about 3.8% of 
adults between 21-84 years of age. The presence of olfactory impairment increases with 
age from 0.6% under 35 years of age to 13.9% at 65 years of age or older (86). Age is 
suggested to exhibit a negative influence across all olfactory tasks (64,68,74,87), 
alongside sex where female participants outperform the male counterparts in olfaction 
sensitivity tests. The prevalence of olfactory impairments is also higher in men than in 
women (74,88). The loss of olfaction with ageing has been linked to changes in non-
olfactory elements of the nose (airway patterns or mucous composition), olfactory 
neuroepithelium (reduced surface area), OB function (reduction of mitral cells in the 
OB) (26,89,90), central brain regions involved in olfactory functions and neurochemical 
changes in the brain (36,91).  
 
 
1.3.2 Alzheimer’s disease  
 
AD is characterised by neuropathological changes, which includes neurofibrillary tangle 
formation, neurotic plaques and atrophy. This progressively leads to deficits in 
functions of memory (such as amnestic presentation), language and visuospatial 
capacities (36,92). The presence of olfactory impairments at the early stages of AD has 
been linked to several factors occurring initially at the EC, one of the main terminals for 
the PC and neuropathological changes in the OB (35,36,93,94). Nobel prize winners M. 
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& E.B. Moser also demonstrated in 2005 that the nerve cells in the EC represent ‘grid 
cells’ that helps with spatial navigation alongside ‘place cells’ in the hippocampus. This 
was discovered in 1971 by Nobel prize winner, J. O’Keefe (95), who indicated that EC 
acts as a personal human guidance system (96). This raises the question whether deficits 
in EC that lead to impairments in spatial navigation in patients with AD could, in fact, 
be a result of olfactory impairments present in the EC, one of the primary olfactory 
cortical areas in the human brain. 
 
In all patients with AD, mitral cells in the OB present AD-type pathology (26,97). This 
includes the presence of excess tau and amyloid precursor protein (morphology of the 
molecular compounds of AD) (98–100), in conjunction with reduction of cerebral blood 
volume (101) and thinning of the EC (main end-terminal for the olfactory system) 
(102,103). AD presents a characteristic pattern of neurofibrillary tangle formation that 
initiates in the entorhinal region and the adjoining temporal neocortex. This pattern of 
AD-pathology then extends to other structures in an expected manner (detailed in 
Figure 1.3) (104). According to an article by Braak & Braak (104), the sequence of 
neurofibrillary tangle formation in patients with AD allows the distinction of three main 
stages: transentorhinal, limbic and neocortical stages. Impairments in the EC are also 
perceived as the link to olfactory dysfunction in the associated interconnected cortical 
regions (101).  
 
Looking at the performance of olfactory tests in patients with AD, ODT (105), ORT 
(69,106–108) and OIT (69,70,72,107,109–113), are impaired from the earliest stage of 
AD. Olfactory dysfunction in the aforementioned testing modalities in patients with AD 
also represents olfactory functions that require associated cognitive load. In comparison, 
impairments in OTT in patients with AD are present in later stages of the disease in 







Figure 1.3. Distribution patterns of AD pathology (amyloid deposits).  
Stage 1(A) shows AD pathology in basal sections of the neocortex. Stage 2 (B) shows 
AD pathology in all neocortical association areas. Stage 3 (C) shows AD pathology in 
all areas of neocortex including sensory and motor association areas (darker regions 
suggest increased number of AD pathology accumulation). Retrieved from Braak & 
Braak (Pg. 244; original publisher: BioMed Central) (104). 
 
 
1.3.3 Parkinson’s Disease  
 
PD is associated with a reduction of nigrostriatal dopaminergic neurons in distinctive 
circuits of the brain (36,117), with impairments including tremor, bradykinesia of 
movement and postural instability. Due to these impairments, patients with PD often 
present poor balance and coordination in movement (36). Olfactory impairments in 
patients with PD are also one of the earliest non-motor symptoms, preceding motor 
symptoms by several years (34,118). These olfactory impairments can differentiate 
patients with PD from healthy controls better than the clinical motor tests (34,119),  
single-photon emission computed tomography imaging of dopamine transporters 
(34,120) or patients with neurological conditions that resemble PD. This includes 
neurological conditions such as progressive supranuclear palsy (121,122), multiple 
system atrophy (122,123), corticobasal degeneration (122) or essential tremor 
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(124,125). In patients with PD, impairments were present in OIT (69,124,126,127), 
ODT/ORT (69,73,106) and STT (91) from the earliest stages of the disease. 
 
Impairments in patients with PD progresses in neuropathological stages, which are 
marked by continuous development of distinctive inclusion body (branching Lewy 
neurites- LN) within cellular processes and as granular aggregations and spherical pale 
bodies (128,129). LN are present from the earliest stage of PD, identified in the anterior 
olfactory nucleus, the OB, and the DMV (130). The spread of LN throughout the stages 
of PD (Figure 1.4), initially begins at the DMV. PD-pathology is initiated here due to 
due to the presence of large-long projection, unmyelinated preganglionic fibres (which 
are more vulnerable to intraneuronal aggregates associated with PD pathology). These 
preganglionic fibres connect the central nervous system with the postganglionic nerve 
cells of the enteric nervous system (128,131,132). This pathology spreads throughout 
the subcortical regions and eventually reaches the cortical areas in later stages of PD 
(34,128,133). The spread of PD pathology indicates the existence of a connection 
between the VN and the olfactory processing areas of the cortex that facilitates the 
origin of early olfactory dysfunction in PD (128,133,134).  
 
 
Figure 1.4. The Braak stages of PD pathology.  
In this figure, initiation sites for the pathology of PD can be observed from the OB and 
medulla oblongata, which then progresses into cortical regions. The diagram suggests 
that α-synuclein-related pathology is initiated in the periphery from the olfactory 
epithelium or vagal inputs and eventually leads to widespread α-synuclein-related 
pathology across the cortex (Braak stages 5 and 6). Retrieved with permission from 
Doty (34) (Licence no: 4335121200258). 
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1.4 Stimulation techniques of the vagus nerve and background 
of olfactory system modulation studies 
 
Neuromodulation of the VN can be performed using a direct or an indirect approach. 
Direct stimulation of the VN can be invasive or non-invasive. Direct invasive VNS can 
be performed using an implantation of stimulator devices over the cervical segment of 
the VN with surgery (9,135). An example of this method includes the ‘NeuroCybernetic 
Prosthesis’ system (size of a pocket watch), which is implanted into the chest wall (left 
side) with bipolar electrodes that are wrapped around the left VN [Figure 3 in George & 
Colleagues (136)]. Direct, non-invasive VNS procedures comprise of transcutaneous 
stimulation of the cervical segment of the VN [Figure 3 in Yuan & Silberstein (9)] or 
the auricular branch of the VN (Figures 1.6 and 2.4 A-B) (9,137). In comparison, 
indirect, non-invasive VNS includes the stimulation of peripheral nerves (Figure 2.2), 
which can antidromically (conducting nerve impulses in the opposite direction in 
comparison to the standard) stimulate VN brainstem nucleus. So far, the stimulation of 
common peroneal nerve and MN results in the activation of the VN brainstem nucleus 
(such as the NTS) (138). So far, there is no invasive, indirect stimulation studies of the 
VN in the existing literature.  
 
In the current literature, effects of neuromodulation on several cranial nerves and its 
subsequent effects on olfactory functions have been investigated. This includes the 
olfactory, trigeminal, facial, glossopharyngeal and vagus nerves(2–8). As chemical 
sense shares a mutual interaction (e.g. in aroma perception during eating, a combination 
of gustatory, olfactory and trigeminal information is processed), studies into cranial 
nerve interactions with olfactory functions have been studied collectively. Some studies 
have addressed specifically the trigeminal nerve as it has been understood to play a 
large role in perception of single odorant or mixtures of odours (2,4,6,7).  However, 
relatively little investigation has been performed in the existing literature into the 
interaction between the VN, using direct or indirect (MNS) VNS on olfactory function 
(8,139). In 1984, using direct, invasive cervical VNS, Garcia-Diaz & colleagues have 
demonstrated an increase in the activity of the OB after high frequency (80 Hz) VNS, 
but not after low frequency VNS (10 Hz) in animal models (1). Frequency is defined as 
the number of occurrences of a repeating event per unit of time. In this respect, low 
frequency stimulation incurs more time between repeated events in comparison to high 
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frequency stimulation. So far, VNS in human subjects have used invasive, approaches 
under low frequencies, which could not achieve the same improvement in olfactory 
function (8,23). There are currently no studies exploring the use of direct or indirect 
methods of VNS under high frequency stimulation for a potential effect on olfactory 
function in humans.  
 
 
1.4.1 Use of indirect, non-invasive vagus nerve modulation through the 
median nerve  
 
1.4.1.1 Anatomy and functions of the median nerve 
 
The MN is a branch of the medial and lateral roots of the brachial plexus. The MN runs 
from the axilla into the arm and passes through to the forearm (between the humeral and 
ulnar heads of the pronator teres) where it innervates the flexor muscles (with the 
exception of flexor carpi ulnaris - Figure 1.5). The MN passes through the midline of 
the wrist and after passing through the carpal tunnel to the hand, innervates the thenar 
muscles and lateral two lumbricals in the hand. The MN innervates the thumb, index 
finger and the middle finger (140). Specific innervation of the MN on muscles of the 
forearm and the hand are indicated in Figure 1.5. The primary motor and sensory 
function of the MN is represented in the primary and secondary somatosensory cortex 
(S-I and S-II respectively) (141–144) alongside several accessory areas of the cortex 
(such as supplementary motor area; SMA) (140).  
 
1.4.1.2 Median nerve stimulation in the existing literature 
 
Stimulation on the MN was initially performed using manual acupuncture. This was an 
ancient, traditional Chinese method used on the Neiguan acupuncture point 
(pericardium meridian of acupuncture point 6; PC-6) on the MN. Using this method, 
MNS was performed for treating various functional diseases. This included 
gastrointestinal diseases (145,146), gastroparesis (147,148), functional dyspepsia 
(15,149), constipation (150) and irritable bowel syndrome (151–153). Alternatively, 
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stimulation of the MN has also been implemented in alleviating symptoms of nausea or 
vomiting in clinical settings (such as post-surgery or chemotherapy, pregnancy and 
motion sickness). In addition, it is also used for other clinical conditions such as dealing 
with addiction, reducing stroke, reduction of headache, menstrual cramps and tennis 




Figure 1.5. Displays the trajectory of the MN through the forearm and hand.  
All flexor muscles in the forearm (exception of flexor carpi ulnaris) that is innervated by 
the MN is included along with the thenar muscles of the hand. Blue regions highlighted 
in the images of the hand (right-hand side) indicate the innervation of the MN on the 
digits of the hand. Additions to the original image includes the label of MN and PC-6 
Acupoint (Neiguan acupuncture point; red square zone) using black arrow heads and 
electrode stimulation sites (labelled using green zones) in Experiment 1. Retrieved and 
edited from Netter & Colleagues (140).  
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1.4.1.3 Use of median nerve stimulation (indirect vagus nerve stimulation) on 
gastric mobility and alleviation of nausea and vomiting  
 
Over the past couple of decades, MNS progressed from manual acupuncture techniques 
(10,13,142) to electroacupuncture (EA-a modification of the acupuncture technique 
using electrical current) (10,12,14,144) and more recently, the use of transcutaneous 
electrical nerve stimulation (TENS-detailed in chapter 2.1.3) (10,157–159). The use of 
low frequency (10-25 Hz) EA-MNS has demonstrated an effective control of gastric 
mobility through increased gastric emptying and the ability to normalise gastric 
dysthymia (12,14,15). The VN is understood to be solely responsible for the control of 
gastric acid secretion, which is also modulated indirectly through the use of MNS in 
animal (14,17) and human studies (15,16). In this context, the MN can be understood to 
stimulate the VN in an indirect manner. This demonstrates the potential effects of MNS 
on olfactory regions through an indirect stimulation of the VN.  
 
In a previous article by Ouyang & colleagues (17), low frequency MNS accelerated 
gastric emptying of liquid and improved gastric slow-wave rhythmicity. Both of these 
functions were attributed to an indirect stimulation of the VN using MNS. Furthermore, 
effects on gastric function using MNS did not occur after vagotomy, similar to other 
studies using animal models (15,19). In a similar manner to improving gastric function, 
past literature has indicated that MNS can be used to ameliorate nausea and vomiting 
through the VN (10–16,155,160). Furthermore, after bilateral truncal vagotomy was 
performed in animal models, alleviation of nausea and vomiting via MNS were 
substantially reduced (14,161). Sense of smell, along with senses of vision and taste, are 
key contributors to inducing nausea or vomiting as the first line of defence against 
dangerous or contaminated food (162). This suggests the potential role of MNS on 
olfactory function.  
 
It is indicated that the effects on gastric function (increased gastric motility) through 
MNS occurs through the indirect stimulation of the VN (14,15,17–19). The potential 
pathway could be through the NTS where the MN projects to the DMV, which enables 
the modulation of gastric function (21,138,163). Both the DMV and NTS are VN 
brainstem nuclei. It is also indicated in past literature that VNS is proportionate to 
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gastric distension (20,164,165). In addition, the periglomerular cells of the OB, which 
respond to gastric distension also respond to VNS in a similar manner (20–22). 
Therefore, it could be hypothesised that the effects of MNS could potentially follow the 
same trajectory of the VN, through the NTS to areas in the cortex (166,167) that 
correspond to processing olfaction (with connections to the periglomerular cells in the 
OB). Although these previous studies support the indirect stimulation of the VN 
(through MNS), there are no neuronal tracing studies looking at the interconnection 
between the neural pathways of the MN and the VN brainstem nucleus. However, there 
are studies that indicate that the MN can activate the NTS (19,138,156,163,168,169). 
Although existing literature on MNS has investigated the effects of MNS on the S-I 
using low frequencies (141–144,154), to date, there are no studies looking at the effects 
of MNS, with either, high or low frequencies, on its potential effects on cortical regions 
of olfactory functions or olfactory function. 
 
 
1.4.2 Use of direct, non-invasive auricular stimulation of the vagus nerve 
 
1.4.2.1 Anatomy and function of the vagus nerve 
 
The VN is the tenth cranial nerve, with the superior segments attached to the medulla 
through multiple rootlets. The VN exits the skull through the jugular foramen and 
travels down the neck as the cervical segment of the VN. Each of the cervical segments 
of the VN lies within the carotid sheath, between the carotid artery and the jugular vein. 
The VN contains sensory and motor fibres and is considered the ‘wanderer’ as it has a 
large range of distributed branches throughout the whole body (57). Dorsal to the skull, 
the VN leaves the jugular foramen to pass through the facial canal and distributes to the 
posterior aspect of the external ear canal and external ear (18,137,170). Sensory fibres 
of the VN innervate a number of structures that includes the larynx, trachea, heart, 
lungs, oesophagus, stomach, small intestine and gallbladder. The cell bodies of these 
sensory VN fibres lie in the jugular and nodose ganglia and terminate in the medulla. 
The somatic motor fibres of the VN innervate the muscles responsible for swallowing, 
with most of the motor fibres being autonomic (parasympathetic fibres). They are 
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thought to originate in the medulla and extend to various areas of the autonomic ganglia 
and finally the muscles of the pharynx, larynx, thoracic and abdominal organs (9,57).  
 
The VN consists of three afferents (sensory; general somatic afferent, general visceral 
afferent and special visceral afferent) and two efferent types (general visceral efferent 
and special visceral efferent). They project to four different vagus nuclei: spinal nucleus 
of the trigeminal nerve, NTS, DMV and nucleus ambiguous. In the context of this 
thesis, we will focus on the NTS and DMV brainstem nucleus of the VN. The NTS is a 
series of nuclei, organised in a topological manner and handles the major viscerosensory 
information of the VN. In the vago-vagal reflex, this structure receives signals 
(mechanical and chemical stimuli) from the gut wall receptors. In response, the NTS 
integrates hormonal and visceral neural signals and sends feedback to the DMV. In 
contrast, the DMV is the major motor brainstem nuclei of the VN and transmits 
monosynaptic vago-vagal feedback to the gastrointestinal tract and plays a key role in 
gastric motility and secretion (21,135). 
 
Looking exclusively at the sensory auricular VN (Arnold branch), it can be stimulated 
through specific portions of the external ear. The ear can be separated into multiple 
sections (Figure 1.6A). The external portion of the ear consists of the auricular and the 
external auditory meatus (ear canal), closed off from the inner ear by the tympanic 
membrane. Specifically, the concha, is separated by the crus of the helix into an upper 
(cymba) and lower (cavum) parts. In previous studies looking at the AbVN, it is 
indicated that the AbVN reach the external ear in humans with the aid of two divisions 
that are formed in the facial canal. One division follows the posterior wall of the 
external ear canal to the cavum and cymba conchae area of the auricular skin (Figure 
1.6B) while the other division moves through the posterior auricular nerve of the facial 
nerve, following the route of the posterior auricular nerve in the posterior aspect of the 
external ear (Figure 1.6C) (171–173).  
 
The AbVN (Arnold branch) is only distributed to the helics minor muscle zone located 
at the cymba concha region of the external ear (Figure 1.6B) (173,174). The majority of 
the medial and lateral surfaces of the external ear is innervated by the great auricular 
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nerve (third cervical nerve). The medial surfaces are innervated by the AbVN while the 
superior surfaces are innervated by the lesser occipital nerve. The lateral external ear is 
also innervated (to a lesser extent of the third cervical nerve) by the AbVN and in the 
superior regions, the trigeminal nerve. There are also some minor innervations through 





Figure 1.6. Anatomy of the external ear, including innervation zones of cranial and 
spinal nerves and electrode placement regions of Experiment 2.  
A) Anatomical divisions of the external ear. The concha region of the external ear is 
divided into two divisions (superior portion pertaining to cymba conchae-green region 
while inferior portion is the cavum conchae-yellow region). The figure is modelled from 
Alvord & Farmer (174). B) Anatomical picture of the ear highlighting the area of 
innervation of the AbVN (blue regions over cymba and cavum conchae), facial nerve 
(innervation represented using circular red sites), trigeminal nerve innervation (green 
region), C2 spinal nerve innervation (yellow region). The figure is modelled from 
Cakmak & colleagues (177). Electrode placement in Experiment 2 marked with black 
dotted line. C) Posterior aspect of the external ear, with the auricular VN innervation 
marked in blue region. The figure is modelled from Peuker & Filler (170). Electrode 
placement in the posterior aspect of the external ear is marked with black dotted line.  
 
 
In animal models, tract-tracing method using an application of horseradish peroxidase 
was used to show that the AbVN projects to the NTS, spinal trigeminal nucleus and 
other sensory nuclei in the brainstem (178). This was also consistent with studies in 
human subjects (137,178–180). In humans, auricular VNS resulted with activation of 
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primary and higher-order central projections of the VN (such as the insula, amygdala, 
nucleus accumbens, hypothalamus and brainstem) (178–180). Auricular VNS can also 
stimulate the NTS (137) when the stimulation was provided to the conchae region of the 
external ear. In addition, stimulation of the AbVN in human subjects performed outside 
the conchae region of the external ear reported no evidence of NTS activation (179–
181). Therefore, in this context, the use of auricular VNS displayed activation of the VN 
brainstem nuclei (NTS).  
 
1.4.2.2 Background of vagus nerve stimulation and its interactions with olfactory 
bulb  
 
The first use of VNS was initially performed by J. Corning in the late 19th century to 
treat epilepsy (9,182). Until the mid-1980s, it was not understood if there were 
opportunities to use electrical stimulation of the VN as a means of potential therapy (9). 
This changed in 1992 when the use of VNS showed the ability to stop seizures in 
animal models (183). This led to interest in the field of neuromodulation, using VNS in 
human studies. It was commonly performed in the left cervical VN as a potential 
therapy for patients with intractable/medically refractory epilepsy (9,138,184,185). 
Currently, invasive VNS is currently available for multiple conditions that include 
intractable epilepsy, chronic treatment-resistant depression (186), pain (186,187), 
primary headaches and medication-overuse headaches (188). 
 
In a previous article by Garcia-Diaz & colleagues (1), invasive VNS under high 
frequencies demonstrated the ability to modulate the neuronal activity of the OB for the 
first time, on animal models. This study indicated that the ipsilateral OB neurons 
displayed an increase in firing activity under high frequency (80 Hz) VNS but not under 
low frequency (20-40 Hz) VNS in rat-animal models. In subsequent studies, invasive 
VNS in human patients with medically intractable epilepsy (8) and therapy-resistant 
depression (23), used low frequency stimulation, where no significant effects of VNS 
on functional olfactory tests were found. However, the use of high frequency VNS, 
previously demonstrated in animal models to be effective in modulating olfactory 
performance (1), was not performed. In fact, present research in VNS still needs to 
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address whether high frequency VNS, as demonstrated in previous research on animal 
models (1), is capable of modulating olfactory performance in human subjects. 
 
1.4.2.3 Exploration in the beneficial use of non-invasive, direct vagus nerve 
stimulation 
 
In one example of invasive neuromodulatory technique directly to the VN (Neuro 
Cybernetic Prosthesis -VNS), electrodes are attached to the left side VN below where 
the superior and inferior cervical branches come off. The use of unilateral left side VNS 
has shown bilateral functional projections into the brain (8,189) while reducing its 
innervation on cardiac function in comparison to the right side VN (134,190). However, 
with the use of invasive VNS, several issues needed to be addressed due to the invasive 
nature of neuromodulation. This includes cases of delayed arrhythmias or syncope after 
long-term use (191), VN trauma causing unilateral vocal cord dysfunction and dyspnea 
(192), sleep apnea (193), paraesthesia and pain (194). Majority of invasive VNS studies 
exhibit small patient samples, due to the difficulty in obtaining ethical approval to use 
this method on healthy subjects (9,137). 
 
Previous studies in animal models have demonstrated that the auricular VN can activate 
the NTS (178,195). This was followed up in a recent article by Frangos & colleagues 
(137) exploring the use of non-invasive auricular VNS through the cymba conchae in 
human subjects. In this study, the use of electrostimulation at the conchae region of the 
external ear had a significant effect on the central projections of the VN, including the 
NTS and multiple areas of the cortex (subthalamic nucleus, periaqueductal gray, 
thalamus, amgydala, insula, nucleus accumbens, hypothalamus, bed nucleus of the stria 
terminalis and additional higher order projections) (137). This was the same neural 
circuits activated by invasive, direct VNS in the existing literature (196,197). Therefore, 
this highlights the feasibility to use non-invasive approaches of VNS that avoids 





1.5 Exploration of the olfactory network using near-infrared 
spectroscopy 
 
Neuroimaging as a technique provides an opportunity to detect activation of the cortex 
in association with olfactory tests and different neuromodulatory techniques. 
Neuroimaging techniques such as functional magnetic resonance imaging (fMRI) and 
NIRS allows for non-invasive measurement of cerebral activation, along with high 
spatiotemporal resolution and detection of metabolic changes that could be potential 
precursors to diseases. These techniques also allow the monitoring of the brain during 
or in response to treatment and the data from neuroimaging techniques also allows for 




1.5.1 History of near-infrared spectroscopy 
 
The first use of spectroscopic measurement was used on in vivo tissue in 1932. In this 
study, optical characteristics of haemoglobin was observed (202). This study was 
followed up ten years later with the use of a practical ear oximeter for aviation purposes 
(203). This technique was used in a study by Millikan (203), which modified the 
previous technique to obtain absolute values of oxygen saturation of arterial blood 
(204). This was used till the 1970s as a clinical method of ear oximetry. There were still 
limitations regarding the stability of measuring continuous monitoring of oxygen 
saturation in the presence of superfluous assumptions for the calibration process. These 
issues were addressed in 1974, with the use of pulse oximetry. Pulse oximetry utilised 
the pulsation of arteries, allowing for an accurate measurement of oxygen saturation of 
arterial blood directly. Using this method, several studies in the 1980s demonstrated the 
effectiveness of the NIRS as an useful, non-invasive technique for rapid detection of 
tissue oxygenation (205–208).  
 
In past literature, electroencephalography (EEG) has been used to detect changes in 
brain activity under different odour patterns (209–211). This type of technology, 
however runs the risk of data misinterpretation due to spatial smearing that occurs 
during the recording of the scalp EEG, in addition to presenting data with low 
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spatiotemporal resolution (31). Conversely, numerous studies have displayed the 
effectiveness of the NIRS to eliminate the issues of EEG and present high 
spatiotemporal resolution (31–33). NIRS uses the modified Beer-Lambert law for the 
light attenuation changes through the illuminated tissue, allowing a non-invasive 
measure of tissue oxygenation (199). The use of regional haemoglobin oxygen 
saturation (rSO2) measurement in the NIRS allows the recording of continuous and non-
invasive measure of cerebral regional oxygen balance (oxygenated and deoxygenated 
haemoglobin concentration) in the cortex (31–33,212,213).  
 
 
1.5.2 Use of near-infrared spectroscopy in conjunction with olfactory 
testing 
 
In past literature, several studies has used NIRS to monitor the activation of the OFC 
during the presentation of olfactory stimuli (31–33,212–214). Based on previous 
literature on fMRI techniques, an article by Harada & colleagues (31) observed the 
effects of smelling different odours (vanilla essence, strawberry essence or 3-
methylindole) on the OFC, temporal lobes, parietal lobes and the occipital lobes using 
NIRS. They found that oxygen haemoglobin (HbO2) concentration only increased over 
the OFC during the presentation of olfactory stimulus (31). This was supported by 
research that followed, using NIRS where increased OFC activation was present after 
the presentation of olfactory stimuli (33). NIRS results in the previous studies (31–33) 
are also supported by fMRI studies where olfactory impression is indicated to be 
processed in the lateral and anterior orbitofrontal gyri of the frontal lobe (157,215–221). 
Specifically in primate models, neurons in the OFC only displayed responses to the 
presence of olfactory stimulus (217). All aforementioned studies support the use of 







1.6 Present aims and objectives 
 
In summary, existing literature indicates the potential of direct (auricular VNS) and 
indirect (MNS) stimulation of the VN in the modulation of olfactory function. The use 
of MNS in past literature in both animal and human studies has demonstrated a positive 
effect in gastric mobility (14,15,17,20–22) and alleviation of nausea and vomiting (10–
16,155,160). Both of these effects using MNS occurs indirectly through the VN. 
Separately, the use of direct, high frequency VNS has shown to be effective in directly 
modulating the activity of the OB in animal models (1). Stimulation of the MN is also 
understood to improve gastric mobility through the DMV and NTS (VN brainstem 
nucleus) (21,138,163). If vagotomy is then performed, no effects of MNS were 
observed on gastric mobility (15,19) or nausea/vomiting (14,161). Although direct VNS 
under low frequencies have been investigated on the potential effects in olfactory 
function using invasive measures in human models (8,23), the use of non-invasive, 
direct or indirect, high frequency VNS has not been explored in the existing literature.  
 
Therefore, to address the aforementioned gaps in the existing literature, the present 
study was conducted in two separate parts. In part one, the effects of non-invasive, 
indirect VNS (using MNS) on olfactory function was investigated, using high- and low 
frequencies, in healthy, adult, male participants. Olfactory function was assessed using 
OTT, before and after each of the stimulation parameters (high-, low frequency MNS 
and placebo). In part two, effects on both lower-level olfactory function (OTT) and 
higher-level olfactory function (STT) (74,76) were investigated after non-invasive, 
direct auricular VNS (using high- and low frequency stimulation and placebo) in 
healthy, adult, male participants. Supplementary NIRS recording of the OFC was also 
included in the second experiment to observe the activation of the OFC during olfactory 
testing modalities and neuromodulation of the VN.  
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 2.0 Methods 
 
2.1 Experiment 1: Use of median nerve stimulation (indirect 




Twenty Caucasian-male, healthy, non-smokers (age range = 22-28 years, mean: 24.8 
years, standard deviation: 1.75 years) participated in Experiment 1. Prior to the 
experiment, each of the participants were asked not to consume any food or beverages 
(aside from water) for two hours prior to the experiment. They were also instructed to 
refrain from applying any fragrance product/s on the day, prior to the experiment. This 
study was carried out in accordance with the recommendations of 'Otago Human 
Participants Ethics Committee' with written informed consent from all participants. All 
participants gave an informed, written consent to participate in the experiment, in 
accordance with the Declaration of Helsinki and met the exclusion criteria set for the 
experiment (non-smoker, in a healthy condition and have NZ-European descent-
appendix 2). The experiment was approved by Otago Human Participants Ethics 
Committee (Reference: H16/148) and registered to the Australian New Zealand clinical 






Each participant was given a brief introduction to all the stages of the experiment and 
were instructed to attend three, 30 to 45-mins sessions, with a minimum time of these 
sessions being 24 hrs apart. The experimental room was an isolated environment with 
air conditioning, allowing for a consistent temperature (23 ± 1°C) in the absence of any 
olfactory or visual stimuli representing food or distractions. The participants were 
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instructed not to sniff during the olfactory tests to eliminate the potential effects of 
sniffing itself during the olfactory tests.  
 
The first experimenter seated the participant directly opposite, on a seat. A consent form 
and exclusion criteria sheet (appendix 2) were signed to qualify the participants for the 
study. A brief explanation of the full experimental process and the olfactory test were 
given to the participant. Pre-stimulation (Pre-S) OTT was performed and then the 
second experimenter conducted the allocated stimulation parameter (high frequency 
MNS, low frequency MNS or placebo) that was delegated randomly for each participant 
(enforcing the double-blind design). Lastly, post-stimulation (Post-S) OTT was 
performed after the allocated stimulation parameter (Figure 2.1). 
 
The experimental design of Experiment 1 is in Figure 2.1. A within-participant design 
was enforced. In each session, participants were randomly assigned to one of the three 
experimental conditions: high frequency MNS, low frequency MNS or placebo. The 
order of experimental conditions was counterbalanced across the participants. In 
addition to the exclusion criteria put in place to ensure that all participants were in 
healthy condition for the experiment (see appendix 2), UPSIT-OIT (Sensonics 
International, Haddon Heights, NJ 08035 USA) and ODMT (Sensonics International, 
Haddon Heights, NJ 08035 USA) were performed by each participant, after the placebo 
session. The results from these olfactory tests were compared to that of previous studies 









Figure 2.1. Schematic sequence of each stage of the Experiment 1 (non-invasive, 
MNS-indirect stimulation of the VN).  
The sequence of the experimental stages includes pre-stimulation odour threshold test 
(Pre-OTT), allocated stimulation parameter, post-stimulation odour threshold test 
(Post-OTT). A brief five-minute introduction, prior to the experiment comprised of 
obtaining participant’s consent and device set up. Labels in diagram: median nerve 
stimulation (MNS), Odour threshold test (OTT). 
 
 
2.1.3 Application of median nerve stimulation 
 
In previous animal and human models, MNS was applied through the stimulation of the 
Neiguan point (PC-6), located in the groove caudal to the flexor carpi radialis and 
cranial to the superficial digital flexor muscles, roughly 3 cm proximal to the corpus 
(10,11,13,15,16,142,143,154–156) (Figures 1.5 and 2.2). Non-invasive MNS was 
applied using ‘TENS ECO-2’ (SCHWA-MEDICO, France) by the same experimenter, 
using TENS for all three different parameters: high (80 Hz) frequency MNS, low (10 
Hz) frequency MNS and placebo (no stimulation but the electrodes were still attached). 
TENS stimulation in the current experiment was performed with the use of two pairs of 
disposable rubber electrode-pads, placed on the MN region of the left forearm, with the 
cathode being 3 cm proximal to the anode (Figure 2.2), similar to previous studies using 
MNS with TENS (158,159). The TENS intensity was adjusted to obtain a tingling 
sensation over the MN territory of the palm (Figure 1.5) and visible flexion response of 
index and/or middle finger (and/or thumb) so that it was confirmed that there was the 
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stimulation of the sensory and motor fibres of the MN in each stimulation session. In 
addition, the stimulation intensity was also kept to a comfortable range for the 
participant to ensure there was no perception of pain. The strength of the MNS 
(amplitude) was between 8-15 mA and the pulse bandwidth was 180 s width bipolar 
square waveform.  
 
Figure 2.2. Location and set-up of the non-invasive MNS (indirect VNS) 
(Experiment 1).  
 
 
2.1.4 Data analysis 
 
The data obtained from the OTT was first checked for normal distribution using 
normality tests with Shapiro-Wilk correction (222), performed on the differences 
between the scores, before and after stimulation for all three parameters (high frequency 
MNS, low frequency MNS and placebo). Data for participants under high frequency 
MNS and placebo condition passed the normality test (p > 0.05). Thus, a paired sample 
t-test was performed on these data. The data for low frequency MNS failed the 
normality test (p < 0.05), so a non-parametric [Wilcoxon signed rank test-used to 
compare two paired samples when the assumptions for the paired t-test are not satisfied) 
was performed as a more suitable method than transforming the data into a normal 
distribution, given our sample size (223–225). All the analyses were performed using 
SPSS software (IBM SPSS Statistics, Ver. 20, St Leonards, NSW).  
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2.2 Experiment 2: Use of non-invasive, direct auricular vagus 




Eighteen Caucasian-male, healthy, non-smokers (age range = 21-38 years, mean: 24.55 
years, standard deviation: 3.8 years) participated in Experiment 2. Before the 
experiment, each participant was asked to abstain from food and beverages (aside from 
water) for 2 hrs preceding the experiment. They were told to abstain from applying any 
fragrance product/s on the day, prior to the experiment. This study was carried out in 
accordance with the recommendations of 'Otago Human Participants Ethics Committee' 
with written informed consent from all participants. All participants gave an informed, 
written consent to participate in the experiment, in accordance with the Declaration of 
Helsinki and met the exclusion criteria set for the experiment (non-smoker, in a healthy 
condition, NZ-European descent-appendix 2). The experiment was approved by Otago 
Human Participants Ethics Committee (Reference: H16/148) and registered to the 





All participants were first informed that the attendance of three, 60 mins sessions with a 
minimum time of these sessions being 24 hrs apart would be required. The experimental 
room was an isolated environment with air conditioning and had no presence of any 
olfactory or visual stimuli representing food or distractions. A consistent temperature of 
23 ± 1°C was also kept in the experimental room. Each participant was instructed to 
avoid sniffing during the olfactory tests to avoid its potential effects on olfactory tests or 
NIRS recordings.  
 
The participant was seated directly opposite the first experimenter. First, a consent form 
and an exclusion criteria sheet were signed by each participant (see appendix 2). This 
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was followed by a brief explanation of each of the experimental stages, including the 
use of NIRS and the two different olfactory tests (OTT and STT) that would be 
performed. NIRS electrodes were placed on the participant, followed by each stage of 
the experiment (Figure 2.3). After the pre-stimulation olfactory tests (Pre-S OTT and 
Pre-S STT), the second experimenter conducted the allocated stimulation parameter 
(high frequency VNS, low frequency VNS or placebo) that was delegated randomly for 
each participant (enforcing the double-blind design). This was followed by the post-
stimulation olfactory tests (Post-S OTT and Post-S STT).  
 
Experiment 2 followed a within-participant design. In each session, participants were 
randomly assigned to one of the three experimental conditions: high frequency VNS, 
low frequency VNS or placebo. Orders of experimental conditions were 
counterbalanced across the participants. Supplementary to the exclusion criteria put in 
place to ensure that all participants were in a healthy condition for the experiment (see 
appendix 2), OIT (Sensonics International, Haddon Heights, NJ 08035 USA) and 
ODMT (Sensonics International, Haddon Heights, NJ 08035 USA) were completed by 
each participant, after the placebo session. The results from these olfactory tests were 
compared to that of past studies (65,66) to ensure that each of the participants met a 
standard criterion of normative, healthy response. 
 
 
2.2.3 Application of non-invasive, direct auricular vagus nerve stimulation 
 
Non-invasive, direct auricular VNS was applied using ‘TENS ECO-2’ (SCHWA-
MEDICO, France) by the same experimenter, using TENS of three different parameters: 
high frequency VNS (80 Hz), low frequency VNS (10 Hz) and placebo condition (no 
stimulation but the electrodes was still attached). In the current literature on cranial 
nerves, it has been indicated that the parasympathetic axons of VN influence the human 
ear with the support of two divisions of the AbVN. The first division of the AbVN 
follows the external ear canal dispersing primarily to the cavum and cymba conchae 
area of the auricular skin. The second branch of the AbVN passes through the posterior 
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auricular nerve of the facial nerve, trailing the route of the posterior auricular nerve 
(171–173).  
 
To stimulate both division of the AbVN, the current experiment implemented VNS to 
the internal (covering the cavum concha and extending to cymba concha) and external 
portions of the left ear (Figure 2.4 A and 2.4 B). The left VN is the preferred side of 
stimulation as it avoids cardiac effects, in comparison to the right VN, which innervates 
the cardia atria (134). The strength of the VNS (amplitude) was between 10-15 mA and 
the pulse bandwidth was 180 s width bipolar square waveform. Stimulation through 
the AbVN was only performed if there was no perceived pain by the participant and the 
strength of the VNS (amplitude) was selected to meet a comfortable range for each 





Figure 2.3. Schematic sequence of each stage of the Experiment 2 (non-invasive, 
direct auricular VNS).  
The sequence of the experimental stages includes pre-stimulation odour threshold test 
(Pre-OTT), pre-stimulation supra-threshold test (Pre-STT), allocated stimulation 
parameter, post-stimulation odour threshold test (Post-OTT), post-stimulation supra-
threshold test (Post-STT). A brief five-minute introduction, prior to the experiment 
comprised of obtaining participant’s consent and device set up. Labels in diagram: 





2.2.4 Data analysis 
 
Data from the NIRS was transferred to the ‘INVOS’ software (INVOS Analytics Tool, 
Ver. 1.2.1, Minneapolis, USA), which accommodated data presentation. We used 
average (mean) recordings of venous weighted regional oxygen saturation (VWrSO2 %) 
of specific time periods marked for each experimental stage (Figure 2.3), methods used 
in the analysis of NIRS in previous research (212,226). Repeated-measures analyses of 
variance (ANOVA) were performed separately to the data obtained from all three 
stimulation parameters (high frequency VNS, low frequency VNS and placebo) for 
assessing VWrSO2 (%) changes in the left and right hemispheric OFC across the 
corresponding stages of the experiment (Pre-S, stimulation and Post-S) within 
participants (n=18). Specifically, repeated-measures ANOVA was applied to the OTT 
and STT periods separately in order to provide synchronised analyses of NIRS data with 
the functional olfactory tests and stimulation (i.e., Pre-S STT, Stimulation, Post-S STT 
periods of NIRS and Pre-S OTT, Stimulation, Post-S OTT periods of NIRS).  
 
In addition to the 3-stage analysis of NIRS, an additional 5-stage analysis of NIRS (Pre-
S OTT, Pre-S STT, stimulation, Post-S OTT, Post-S STT, in the order of experiment, 
see Figure 2.3) were also performed to reveal any potential influence of the previous 
olfactory test over the next one that followed correspondingly (OTT effects on STT). 
Post hoc test using Bonferroni correction [for multiple pairwise comparisons between 
the stages of Experiment 2 (227,228)], was applied to understand any significance at 
alpha level of 5% (p < 0.05) in all ANOVA tests. To ensure the baseline activity was 
consistent across three different stimulation parameters for OTT, STT and NIRS data, 
repeated measures ANOVA was also applied to data that was obtained at the Pre-S 
stages (Table 3.3). 
 
For data obtained from the olfactory tests, normality tests using the Shapiro-Wilk 
correction (222) were performed on the differences between the scores before and after 
stimulation for all three parameters (high frequency VNS, low frequency VNS and 
placebo). This test was performed separately for the OTT and STT data.  Data for 
participants under low frequency VNS and placebo condition for OTT and for 
participants under placebo condition for STT, passed the normality test (p > 0.05). Thus, 
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a paired sample t-test was performed on these data. The rest of the data (high frequency 
VNS for both OTT and STT tests, and low frequency VNS for STT test) failed the 
normality test (p < 0.05), so a non-parametric (Wilcoxon signed rank test) (223–225) 
was performed for this set of data. All the analyses were performed using SPSS 
software (IBM SPSS Statistics, Ver. 20, St Leonards, NSW).  
 
 
2.3 Information on the functional olfactory tests and near-
infrared spectroscopy 
 
2.3.1 Odour threshold test – Experiment 1 & 2 
 
The OTT was performed using ‘Snap & Sniff Olfactory Test System’-Sniffin’ Sticks 
(Sensonics International, Model: 02400, Hadden Heights, NJ). The Sniffin’ Sticks test is 
a validated psychophysical tool allowing detailed evaluation of a patient’s olfactory 
performance with high levels of sensitivity and specificity (71). This testing battery 
comprises five blank-odour pens and 15 odorant pens (phenyl ethanol; concentration 
ranges: 10-2 to 10-9, 0.5 log apart).  Inter-stimuli-interval was approximately 3 s; the 
inter-trial-interval was approximately 20 s. The experimental procedure for the OTT 
followed that of previous studies (68,229). A two-alternative forced choice, two-down, 
one-up staircase method was implemented to obtain odour threshold measures, 
following existing literature (68).   
 
In each trial, two pens were presented in a randomised order, one blank and one odorant 
pen, at 2 cm away from the nostrils. The participant was asked to indicate, which pen 
contained the odorant. Two consecutive correct identifications led to one-step down in 
the concentration series for the next trial. One incorrect response incurred an increase in 
concentration by one-step up. The initial presentation was always at the same 
concentration step (10-6). As the test progressed, reversal points could occur when 
concentration of the presented odour changed direction (i.e., increasing to decreasing; or 
decreasing to increasing). Termination of the test was signalled by completion of seven 
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reversal points. Individual thresholds were estimated using the standard data analysis 
method for the staircase test, by averaging the concentrations at, which the last four 
reversal points occurred (68,229).  
  
 
2.3.2 Supra-threshold test – Experiment 2 
 
STT was performed according to existing literature (81) using the odorant ‘Vanillin’ 
(Sensient; CAS number: 121-22-5; purity: 99 %). A series of aqueous solutions with 
varying concentrations – 8ppm (parts per million), 16ppm and 32ppm – were prepared 
using a dilution method. The blank samples in the STT consists of distilled water. The 
STT comprised of three trials, with each trial consisting of five samples in, which two 
were the target samples and three were the odourless samples. Participants were asked 
to identify both of the target samples.  There was a 30 s delay between each sample 
(five per trial) and a further 1 min delay between trials (three trials per stage- Pre-S STT 
and Post-S STT). Participants were awarded a point if both target odours were identified 
and a maximum of three points could be attained.  
 
 
2.3.3 University of Pennsylvania Smell Identification Test – Odour 
Identification Test – Experiments 1 & 2 
 
UPSIT-OIT is a standardised test (The Smell Identification Test™, Sensonics, Inc, 
Haddon Heights, New Jersey), which requires participants to identify, in a four-
alternative multiple-choice format, each of 40 odorants presented on micro-encapsulated 
'scratch and sniff' labels (65,66). As an example, a test item could read 'This odour 
smells most like: (a) chocolate; (b) banana; (c) onion; or (d) fruit punch'. The participant 
must provide a response even if no odour is perceived (the test is forced-choice). The 
dependent measure is the number of items correctly answered. The odorants are 
embedded in a 10-50 µm urea-formaldehyde polymer microcapsules fixed in a 
proprietary binder and positioned on brown strips at the bottom of the test booklets. The 
stimuli are released by scratching strips with a pencil tip in a standardised manner. 
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Above each odorant strip is a multiple-choice question with four alternative responses. 
One point is awarded per correct multi-choice answer, with the total of 40 points that 
can be attained. 
 
 
2.3.4 Odour Discrimination/Memory Test – Experiments 1 & 2 
 
ODMT is a 12 trial test, using microencapsulated, 'target odorants' where an odour is 
presented to the participant followed by four odorants from, which the subject is then 
instructed to select the odour that is identical to the target (first) stimulus. On one-third 
of the trials, a 10 s interval was present between the presentation of the target stimulus 
and the first of the four alternatives. The 10 s interval is delayed further to 30 s and 60 s 
on the other one-third of the trials (in total, four trials with 10 s intervals, four trials with 
30 s intervals and four trials with 60 s intervals). The number of trials in, which the 
target odour was correctly identified behaved as the primary dependent measure. One 
point is awarded per correct selection of the first stimulus matching the answer 
stimulus, with a total of 12 points that can be attained (65,66,230). 
 
 
2.3.5 Near-infrared spectroscopy - Experiment 2 
 
NIRS-COVIDIEN INVOS OXIMETER (Model 5100C-PA, Mansfield, MA) was used 
to record each participant’s activity from the left and the right hemispheric OFC in 
Experiment 2 (set up as shown in Figure 2.4 A-B). NIRS-INVOS uses two near-infrared 
light sources at two different wavelengths (730 and 810 nm) (199) and two photodiode 
detectors. The near-infrared light sources travel to either, a proximal or distal detector, 
in a parabolic path. This enables separate data processing of shallow and deep optical 
signals. An algorithm is used to subtract the distance of the short, proximal detector 
from the longer distance of travel from the distal photodiode detector, thus eliminating 
the inputs of the skin and the scalp (231). This technology through the INVOS-NIRS, 
allows for the localisation in the area of measurement, while avoiding the contribution 
of extra-cerebrally reflected photons, and enables high spatial resolution. This 




The use of NIRS is possible through the measurement of rSO2. This is the continuous 
and non-invasive measure of cerebral regional oxygen balance in the cortex. The 
‘COVIDIEN INVOS OXIMETER’ used in Experiment 2 is a clinically approved NIRS 
device, which measures both the venous and the arterial blood in a 3:1 ratio, monitoring 
brain activity while excluding information from the skin and scalp blood flow. INVOS-
NIRS uses a clinically validated algorithm that allows absolute, real-time data accuracy 
from the cortex (212–214,232–238). With the aid of this algorithm, INVOS measures 
the VWrSO2 (%) in the cortex, which provides real-time information concerning the 
balance of oxygen supply and demand and in turn, calculates the venous oxygen reserve 
(VOR; the remaining oxygen after extraction by tissues and vital organs) (212–
214,232–238).  
 
INVOS-NIRS provides several advantages, which eliminates some previous limitations 
that are presented with the use of NIRS technology. First of all, the wavelength of 
interest (730-810 nm) has the interference of melanin and water, which are also in the 
light spectrum of photon absorption. However, the INVOS NIRS have demonstrated in 
past literature to be unaffected by normal skin pigmentation in adults (239,240). This 
limitation is also reduced by the use of a within-subject design in Experiment 2 that 
reduced potential biasing effects due to inter-individual differences in skin colour. 
Issues surrounding hair (or hair follicles), which can produce excessive photon 
scattering in the NIRS, resulting in artefactual low rSO2 recordings (241) was also 
eliminated in Experiment 2 as the recording area was from the forehead that has no hair 
on the placement of the INVOS-NIRS sensors. The issues surrounding skull and skin 
perfusion issues, which can also alter the NIRS recordings was addressed through the 
use of two specific wavelengths of near-infrared light to determine oxygen haemoglobin 
saturation in the tissue beneath the sensor. With the use of two detectors in shallow and 
deep locations, this allowed the reduction of interference from superficial tissue 
(232,242,243). 
 
In addition, INVOS-NIRS allowed the elimination of artefact through motion artefacts 
of relative movement between an optical fibre and the scalp through the use of signal 
strength index for each channel by a 5-unit bar scale system. In this system, adequate 
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signal strength to measure VWrSO2 (%) accurately, is represented through the 
continuous display of at least one bar (maximum 5 bars) (chapter 6.4.16 and 11.7.4 in 
the INVOS NIRS 5100c manual (231)). In this context (Experiment 2), all sessions were 
performed at maximum signal (5 bars). Disposable INVOS electrodes were also used 
for each participant to ensure the highest data quality and keep the experiment hygienic. 
To ensure maximal stabilisation of the electrodes, cables were held up with a rigid 
headband (Figure 2.4A-B), along with the self-adhesive feature of the disposable 
INVOS sensors. In the context of the clinical validation and extensive literature of the 
INVOS-NIRS (over 600 peer-reviewed publications), NIRS-INVOS was used for the 
present study. With the NIRS, each experimental stage in Experiment 2 (Figure 2.3) 
was marked and once the data from the NIRS was transferred to ‘INVOS’ software 
(INVOS Analytics Tool, Ver. 1.2.1, Minneapolis, USA), it allowed exportation of NIRS 
data into Excel sheets. Here, an average (mean) recording of VWrSO2 (%) (representing 
VOR) for the participant from the left and right hemisphere of the OFC for each 
experimental stage (Figure 2.3) was calculated, methods used in previous literature for 




Figure 2.4. Set-up of the NIRS.  
(A) Set up of the NIRS electrodes on the forehead for Experiment 2. Location and set-
up of the non-invasive VNS (Auricular TENS) electrode in the cavum and cymba 
conchae area of the external ear (Experiment 2). (B) Location of the non-invasive VNS 
(auricular TENS) electrode in posterior aspect of the external ear (Experiment 2). (C) 
The auricular TENS electrode (Experiment 2) (Schwa-Medico, France). Written 
informed consent was obtained from the participant for the publication of this image 
(appendix 1). Retrieved and edited from Maharjan & colleagues (244). 





3.1 Preliminary pre-screening olfactory test results  
 
The results from the OIT and ODMT is presented in Table 3.1. These results were 
compared to the standard criteria required to meet the normative healthy responses put 
forward by Doty & colleagues (65,66). Half of the 20 participants displayed values 
outside of Normosmia in Experiment 1 while 7 of the 18 participants displayed values 
outside of Normosmia in Experiment 2. However, none of the participants in either of 
the experiments displayed total anosmia, which was the exclusion criteria for the current 
experiments and presented olfactory performances in OIT to a standard held in line with 
the existing olfactory research (65,66). All participants also displayed responses in the 
ODMT that corresponds to healthy ranges, in line with existing literature 
(65,66,230,245). In this context, all participants qualified to take part in both of the 
present experiments.  
 
 
3.2 Experiment 1: Use of MNS (indirect stimulation of the vagus 
nerve) to modulate olfactory function 
 
3.2.1 Odour threshold test results 
 
Each participant’s (n= 20) results in the OTT, before and after MNS, for all three 
stimulation parameters (high frequency MNS, low frequency MNS and placebo) are 
presented in Figures 3.1 (A-C). There were no significant differences in OTT 
performance after MNS under any of the three stimulation parameters [high frequency 
MNS, p:0.472 (paired sample t-test); low frequency MNS, p:0.395 (Wilcoxon signed-





Table 3.1 Results from the pre-screening OIT and ODMT from Experiment 1 and 
Experiment 2. 
Participants scores on the OIT and ODMT arranged into the criteria determined by their 
scores in Experiment 1 (n = 20) and Experiment 2 (n = 18). odour identification test 


















 (Total Anosmia) 
0 0 0-7 0 0 
19-25  
(Severe Anosmia) 




0 0 9 1 3 
30-33  
(Mild Microsmia) 
10 6 10 1 4 
34-40 
 (Normosmia) 
10 11 11-12 8 3 
 
 
3.2.2 Intergroup data from the odour threshold test  
 
The results from the repeated-measures ANOVA to determine if there were any 
potential differences in the performance of the OTT in the three different stimulation 
parameters (high frequency MNS, low frequency MNS and placebo) at the Pre-S stage 
of testing is presented in Table 3.2. There were no significant differences in the Pre-S 







Table 3.2. Pre-stimulation OTT result analysis (Experiment 1). 
Results of the repeated-measures ANOVA that assessed if there were potential 
differences in the OTT scores of the Pre-S OTT data in all three different stimulation 
parameters (high frequency MNS, low frequency MNS, placebo) at the Pre-S stage of 
testing. S.D. = standard deviation, OTT score ranges = 2-9, H = high frequency MNS, L 
= low frequency MNS, P = placebo condition. 
Olfactory Test  Stimulation 
Parameter 
Mean S.D. F-Value P-value 
Pre-S OTT 
H 5.79 0.85 
0.482 0.622 L 5.79 0.98 




Figure 3.1 A-C. OTT results (Experiment 1). 
OTT results from each participant before and after each stimulation parameter (high 
frequency MNS, low frequency MNS and placebo) in Experiment 1. Each participant’s 
scores, before (Pre-S OTT) and after (Post-S OTT) each of the stimulation parameters 
[high frequency MNS (A) in red lines, low frequency MNS (B) in blue lines and 
placebo (C)] in green lines, for the OTT (OTT scores range = 2 – 9). 
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3.3 Experiment 2: Use of non-invasive, direct auricular vagus 
nerve stimulation to modulate olfactory functions 
 
3.3.1 Odour threshold test results  
 
Each participant’s results (n = 18) from the OTT, before and after VNS, for all three 
stimulation parameters (high frequency VNS, low frequency VNS and placebo) is 
presented in Figure 3.2. There was no significant difference in OTT performance after 
any stimulation parameters [high frequency VNS, p:0.523 (Wilcoxon signed-rank test); 
low frequency VNS, p:0.186 (paired sample t-test); placebo stimulation, p:0.904 (paired 
sample t-test)].  
 
 
3.3.2 3-Stage odour threshold test - near-infrared spectroscopy results 
(Pre-S OTT, stimulation, Post-S OTT) 
 
In the NIRS recording of the left and right hemispheres in the OFC during the OTT, 
there were no significant differences in VWrSO2 (%) under all three stimulation 
parameters in all stages of the experiment (Pre-S OTT, stimulation, Post-S OTT) (left 
hemisphere, high frequency VNS, p:0.643; left hemisphere, low frequency VNS, 
p:0.570; left hemisphere, placebo, p:0.061; right hemisphere, high frequency VNS, 
p:0.233; right hemisphere, low frequency VNS, p:0.565; right hemisphere, placebo, 
p:0.098). All individual results of 3-stage OTT-NIRS are presented in Figure 3.2. 
 
 
3.3.3 Results of supra-threshold test 
 
Each participant’s results (n = 18) from the STT, before and after VNS stimulation, for 
all stimulation parameters (high frequency VNS, low frequency VNS and placebo) is 
presented in Figure 3.3. Significant differences in STT performances was found after 
high frequency VNS [p:0.021 (Wilcoxon signed-rank test)] but not under the low 
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frequency VNS [p:0.439 (Wilcoxon signed-ranked test) or placebo (p:0.083 (paired 
sample t-test)].  
 
 
3.3.4 3-Stage supra-threshold test – near-infrared spectroscopy (Pre-S 
STT, stimulation, Post-S STT) 
 
In the NIRS recording of the OFC in the right hemisphere, there were significant 
differences in VWrSO2 (%) between the three stages of the experiment after high 
frequency VNS (p:0.031). Post-hoc tests using the Bonferroni correction revealed that 
there were significant differences in NIRS-OFC recording on the right hemisphere 
between Pre-S STT and stimulation stages (p:0.014). There were no significant 
differences in VWrSO2 (%) between the three stages of the experiment after high 
frequency VNS in the left hemisphere (p:0.253), or after low frequency VNS in both 
hemispheres (left hemisphere, p:0.693; right hemisphere, p:0.732) or after placebo (left 
hemisphere, p:0.697; right hemisphere, p:0.849). Individual participant results for 
VWrSO2 (%) from the STT-NIRS stages (Pre-S STT, stimulation, Post-S STT) in both 
hemispheres of the OFC is presented in Figure 3.3. Additional scatterplot chart of each 
individual participant, before and after stimulation parameters (high frequency VNS, 
low frequency VNS and placebo), STT scores and the corresponding right hemispheric 




3.3.5 All stages (5-stage) near-infrared spectroscopy analysis (Pre-S OTT, 
Pre-S STT, stimulation, Post-S OTT, Post-S STT) 
 
An additional repeated-measures ANOVA analysis of all stages (5-stage) (Pre-S OTT, 
Pre-S STT, stimulation, Post-S OTT, Post-S STT; Figure 2.3) in NIRS, for all 
stimulation parameters (high frequency VNS, low frequency VNS and placebo) for the 
left and right hemisphere demonstrated a significance only under high frequency 
stimulation for the right hemisphere (p:0.037) and pairwise comparisons demonstrated 
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the significance (p:0.046, post-hoc tests using the Bonferroni correction) only in 
between the Pre-S STT and stimulation periods of NIRS, similar to the results derived 





Figure 3.2. OTT and OTT - NIRS recording from the OFC (Experiment 2).  
Each participant’s scores, before and after each of the stimulation parameters (high 
frequency VNS, low frequency VNS and placebo) for the OTT (OTT scores range = 2 – 
9), and each participant’s recordings for all three stages of Experiment 2 (pre-
stimulation OTT; Pre-S, stimulation and post-stimulation OTT; Post-S) for all 
stimulation parameter (high frequency VNS, low frequency VNS and placebo) from the 
left and the right hemispheres of the OFC, measuring VWrSO2 (%) using NIRS 











Figure 3.3. STT and STT- NIRS recording from the OFC (Experiment 2).  
Each participant’s scores, before and after each of the stimulation parameters (high 
frequency VNS, low frequency VNS and placebo) for the STT (STT scores range = 0 – 
3), and each participant’s recordings for all three stages of the experiment (pre-
stimulation STT; Pre-S, stimulation and post-stimulation STT; Post-S) for all 
stimulation parameter (high frequency VNS, low frequency VNS and placebo) from 
both the left and the right hemispheres of the OFC, measuring VWrSO2 (%) using NIRS. 
The numbers in each line for the STT performance represents the number of cases that 
represent the corresponding result. *Statistically significant (p < 0.05). Retrieved from 









Figure 3.4. Supra-threshold test (STT) and STT - NIRS recording from the right 
hemisphere of the OFC using direct high frequency VNS (Experiment 2).  
Scatterplot graph which displays each participant’s scores, before and after high 
frequency VNS for the STT scores (scores range = 0 – 3) in combination with 
participant’s recordings for all three stages of the experiment (Pre-S STT, stimulation 
and Post-S STT) for the right hemispheric OFC, measuring VWrSO2 (%) using NIRS. In 
the STT performance (figure on top), ‘red’ colour represents participants who improved. 
On the STT-NIRS of the right hemispheric OFC recordings (figure on bottom), ‘Red’ 
colour represents improvements (increased VWrSO2 %) in the stimulation stage from 
the Pre-S stage and ‘Orange’ colour represents improvements (increased VWrSO2 %) in 





Figure 3.5. Supra-threshold test (STT) and STT - NIRS recording from the right 
hemisphere of the OFC using direct low frequency VNS (Experiment 2). 
Scatterplot graph which displays each participant’s scores, before and after low 
frequency VNS for the STT scores (scores range = 0 – 3) in combination with 
participant’s recordings for all three stages of the experiment (Pre-S STT, stimulation 
and Post-S STT) for the right hemispheric OFC, measuring VWrSO2 (%) using NIRS. In 
the STT scores figure (figure on top), ‘red’ colour represents participants who 
improved. On the STT-NIRS of the right hemispheric OFC recordings (figure on 
bottom), ‘Red’ colour represents improvements (increased VWrSO2 %) in the 
stimulation stage from the Pre-S stage and ‘Orange’ colour represents improvements 
(increased VWrSO2 %) in the Post-S stage from the Pre-S stage. Retrieved from 






Figure 3.6. Supra-threshold test (STT) and STT - NIRS recording from the right 
hemisphere of the OFC under placebo condition (Experiment 2). 
Scatterplot graph which displays each participant’s scores, before and after placebo 
condition for the STT scores (scores range = 0 – 3) in combination with participant’s 
recordings for all three stages of the experiment (Pre-S STT, stimulation and Post-S 
STT) for the right hemispheric OFC, measuring VWrSO2 (%) using NIRS. In the STT 
scores figure (figure on top), ‘red’ colour represents participants who improved. On the 
STT-NIRS of the right hemispheric OFC recordings (figure on bottom), ‘Red’ colour 
represents improvements (increased VWrSO2 %) in the stimulation stage from the Pre-S 
stage and ‘Orange’ colour represents improvements (increased VWrSO2 %) in the Post-





3.3.6 Intergroup data from the odour threshold test and supra-threshold 
test, and respective near-infrared spectroscopy recordings from the 
orbitofrontal cortex  
 
The results of the repeated-measures ANOVA that examined any potential differences 
of olfactory tests (OTT and STT) and NIRS analysis (VWrSO2 %) in all stimulation 
parameters (high frequency VNS, low frequency VNS and placebo) at the Pre-S stage of 
testing is presented in Table 3.3. No significant differences were observed in the Pre-S 
stage for both olfactory tests (Pre-S OTT and Pre-S STT) or the NIRS analysis periods 
of both olfactory tests (VWrSO2 %) under any stimulation parameters (Table 3.3). 
 
 
Table 3.3. Pre-stimulation OTT and STT results and respective OFC-NIRS 
recordings. 
Results of the repeated-measures ANOVA that assessed if there were potential 
differences in the OTT and STT scores and OFC-NIRS recordings of the Pre-S OTT 
and Pre-S STT data in both hemispheres in all three different stimulation parameters 
(high frequency VNS, low frequency VNS, placebo) at the Pre-S stage of testing. S.D. = 
standard deviation, OTT score ranges = 2-9, h = hemisphere, H = high frequency VNS, 
L = low frequency VNS, P = placebo condition. Retrieved from Maharjan et al., (244). 
 





Mean S.D. F-Value P-value 
Pre-S OTT 
H 6.02 1.41 
0.099 0.889 L 5.83 1.71 
P 5.92 1.53 
Pre-S STT 
H 1.55 1.20 
2.006 0.152 L 1.78 0.94 
P 2.11 0.76 
Left H Pre-S OTT  
H 76.72 9.73 
1.156 0.319 L 76.23 8.48 
P 74.72 9.84 
Right H Pre-S OTT 
H 76.65 9.49 
1.663 0.089 L 75.58 8.85 
P 74.26 9.91 
Left H Pre-S OTT 
H 76.01 9.05 
2.129 0.111 L 78.04 9.81 
P 75.55 9.74 
Right H Pre-S STT 
H 77.35 10.06 
2.016 0.149 L 76.21 9.09 





4.1 Main findings 
 
The overall aim of the current study was to investigate the potential effects of non-
invasive, direct and indirect (through the MN) stimulation of the VN on olfactory 
function. The potential effects of non-invasive, direct and indirect stimulation of the VN 
was investigated in healthy, adult, male participants using high- and low frequency 
stimulations. Olfactory sensory tests used in the current experiments included the OTT 
for non-invasive, indirect stimulation of the VN (using MNS) (Experiment 1) and OTT 
and STT for non-invasive, direct auricular VNS (Experiment 2). In addition, NIRS was 
used to measure VWrSO2 (%) of the OFC during the olfactory tests and 
neuromodulation of the direct auricular VN (Experiment 2).  
 
From the results of Experiment 1 and Experiment 2, the current study has come to two 
distinct conclusions. First, the use of non-invasive, indirect VNS (through the MN) 
under high- or low frequencies did not show any modulatory effects on the OTT 
(Experiment 1). And second, to our knowledge, this is the first study to suggest that 
non-invasive, direct high frequency auricular VNS can positively modulate STT in 
healthy, adult, male participants (Experiment 2). The improvement of the STT 
performance in Experiment 2 (non-invasive direct VNS via the AbVN) was supported 
by NIRS recording of the OFC with increased activation (VWrSO2 %) in the right 
hemisphere (Experiment 2). Post-hoc test (Bonferroni correction) after repeated-
measures ANOVA revealed that the increase in cortical activation of the right OFC after 
direct auricular high frequency VNS occurred between the pre-stimulation (Pre-S STT) 






 4.2 Present results in conjunction with existing literature on 
direct and indirect vagus nerve stimulation 
 
The use of direct (auricular VNS) and indirect VNS (MNS) under low frequencies has 
been the basis of existing literature in animal models and human subjects. However, no 
existing literature has focused on the effects of direct or indirect VNS on modulating 
olfactory function. The use of direct, low frequency VNS in the current literature on 
human (8,23) have displayed no effect on olfactory performance under invasive and 
non-invasive techniques. In animal models, direct VNS using low frequency was not 
able to modulate the activity of the OB (1). The absence of effects in both OTT and STT 
after direct VNS using low frequency stimulation in Experiment 2 provides further 
support to the existing literature (1,8,23).  
 
Use of NIRS (Experiment 2) provides additional support, with no significant changes in 
activation of the OFC in both hemispheres under all three stages of the OTT-NIRS (Pre-
S OTT, stimulation, Post-S OTT) or STT-NIRS (Pre-S STT, stimulation, Post-S STT) 
after direct, low frequency VNS. It is worth mentioning that the exploration of low 
frequency VNS in the past literature was performed in patients with medically 
intractable epilepsy (8) and patients with therapy-resistant depression (23). This 
frequency of stimulation was used as it fit the stimulation parameters for patients with 
the aforementioned conditions, instead of using stimulation parameters that could 
potentially impact olfactory function in healthy participants. Due to the conditions of 
the patients (8,23), it was not feasible for previous research on VNS in humans to test 
high frequency VNS used in the current study. This is problematic as direct, invasive 
high frequency VNS (using 80 Hz), was effective in modulating the activity of the OB 
in existing literature on animal models (1). 
 
In animal models, the use of direct, invasive, low frequency VNS has reported 
inhibitory effects on the dopamine system that includes the nucleus accumbens, frontal 
cortex, ventral tegmental area and the striatum (246). In an article by Ziomber & 
colleagues (246), it was indicated that direct, invasive VNS using low frequencies 
displayed similar effects on dopaminergic impairments to vagotomy. Dopaminergic 
system has also been associated with the modulation of ODT and OTT performances 
53 
 
(246). Significant improvements in clinical PD motor symptoms have also been 
associated with direct, high frequency (130 Hz) auricular VNS (177). In this context, it 
was hypothesised that although low frequency VNS, through the potential modulation 
of the dopaminergic system, leads to an impaired VN function, in contrast, high 
frequency stimulation could potentially have the opposite effects (177,247–249). In 
addition, other neurotransmission systems that include serotonergic, cholinergic and 
noradrenergic systems could also be influenced by VNS (Figure 4.1), and effects of 
VNS using separate frequencies (high or low) on these systems needs to be investigated. 
More research is required to encapsulate the exact mechanism of action of how direct or 
indirect, non-invasive high or low frequency VNS affects the dopaminergic, 
serotonergic, cholinergic and noradrenergic systems and in turn, olfactory function.  
 
The use of low frequency MNS in existing literature have been indicated to increase the 
cortical activation of S-I and S-II (141–144). Previous literature on the MN in both 
animal models and human subjects used low frequency MNS to improve gastric 
mobility (12,14–17) and alleviate nausea and vomiting symptoms (10–13,15,16,143). 
Changes in gastric mobility are driven by the DMV and viscerosensory information of 
motility and distension is relayed to the NTS and subsequently to the insula-olfactory 
networks (250) (Figure 4.2). Although the use of olfactory functional test (OTT) 
indicated no improvements after non-invasive low frequency MNS (Experiment 1), it is 
also necessary to test the STT for MNS for a potential change as performed in 
Experiment 2. 
 
In the present study, only non-invasive, direct auricular high frequency VNS 
demonstrated improvements in STT performance (Experiment 2). In addition, there was 
an increased contralateral activation of the OFC (right hemisphere) under STT-NIRS 
recordings. The results of direct, high frequency VNS supports existing literature, which 
suggested that low- and high frequency stimulation could display distinct effects on the 
autonomic nerve system responses (177,247–249). It should be mentioned that there 
was a trend to reduce STT functioning in the placebo group (Experiment 2, Figure 3.3) 
but this did not reach significance (p > 0.05). This could be associated with sensory 
adaptation, which can occur rapidly, within a few seconds and recovery from adaptation 
depends on the initial stimulus. Sensory adaptation can also lead to olfactory fatigue, 
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which can hinder the participant’s ability to detect odours in repeated odours tests (251–
253). Future investigations are required to uncover whether 10 mins between pre-
stimulation STT and post-stimulation STT is sufficient to recover from sensory 
adaptation. In addition, intergroup testing of pre-stimulation STT data indicated no 
significant differences across the three stimulation parameters (Table 3.3). 
 
A limitation in the current study (Experiment 1) is that the effects of indirect VNS 
(using high and low frequency MNS) were only observed on lower-order olfactory 
function (OTT) (74,76). In the exploration of the effects of direct VNS on STT 
performance (higher-order olfactory function) (74,76), improvements were found in 
STT performance, in conjunction with an increase in contralateral OFC activation 
(Experiment 2). These results highlight the need to investigate indirect VNS (using 
MNS) on the higher-order olfactory function (STT). This will help understand whether 
indirect VNS (using MNS) can exert the same improvements in STT performance to 
non-invasive, direct auricular VNS. If the same results in STT performance are detected 
after non-invasive indirect VNS, this would further support existing literature that MNS 
results in the indirect stimulation of the VN (10,12–17,154,160). 
 
Previous studies have stated that different olfactory measures such as the ODT, OIT or 
ORT could be processed under the same cortical/subcortical areas associated with 
olfaction (38). In healthy participants, olfactory functioning in the OTT was highly 
correlated with that of the OIT (83,254). However, no measures of STT were performed 
in conjunction with OTT (38). In fact, some articles have suggested that STT measures 
vary from other forms of olfactory tests (ODT, OMT, OIT), including OTT (82,83). 
This is supported by our current study (Experiment 2) where direct, auricular VNS 
under high frequency stimulation improved STT performance but it did not affect OTT 
performance. It is possible that the use of neuromodulation in the current study 
(Experiment 2) facilitates olfactory neurocircuitry responsible for STT but not in neural 
circuitry responsible for OTT.  
 
It is understood in the present literature that OTT is governed by sections of the cortex 
that are responsible for low-order olfactory function (such as the OB- peripheral sensory 
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input of olfactory processes) whereas ODT/OIT/ORT/OMT/STT poses more cognitive 
load, and are represented in sections of the cortex that are responsible for higher-order 
olfactory function (27,70,73–76). This could explain the variability seen in Experiment 
2 where no changes were seen in the OTT after direct, high- or low frequency VNS, or 
supplementary recordings of the OFC after OTT stages (Pre-S OTT, stimulation, Post-S 
OTT). It is possible that the lack of improvement seen in the OTT in both experiments 
of the current study was due to healthy participants presenting OTT scores that equate 
to the healthy ranges in past literature (65). Investigations into the potential benefits of 
VN neuromodulation on OTT and STT performance in patients who present olfactory 
impairments (patients with PD and AD) should be investigated in future experiments.  
 
 
4.3 Exploration of neuroanatomy underlying direct vagus nerve 
stimulation 
 
Exploration on the cortical and subcortical structures that are influenced by different 
frequencies of direct VNS can aid in understanding how VNS can result in the 
modulation of cortical areas that correspond with olfactory function. In the past 
literature, only invasive, direct high frequency VNS increased the activity of the OB, 
with the potential effect of VNS through the periglomerular layer of OB in animal 
studies (1). It is also understood that the cholinergic elements of the OB begin at the OT 
(255) and it has been established that the OT modulates the centrifugal control over the 
OB (Figure 4.1) (256). Therefore, this suggests the existence of an oligosynaptic 
pathway by, which the VN has an effect on the OB through the OT. 
 
The OT is heavily innervated by several neuromodulatory centres in the brain and 
brainstem. This includes the amygdala, nucleus gemini of hypothalamus, raphe nucleus 
(RN), locus coeruleus (LC) and the paraventricular thalamic nucleus (NPvt) (257). LC 
and RN can innervate the OT through noradrenergic and serotonergic fibres respectively 
(258,259). RN also operates through a dopaminergic pathway to influence the OT, 
which passes through the ventral tegmental area (260,261). Both the LC (via 
paragigantocellular nucleus) (262) and RN includes afferents from the NTS and it has 
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been established that both structures can be stimulated with auricular VNS 
(137,196,197,263).  
 
The OFC is the secondary order station of the olfactory system that can be modulated 
by OT or directly by LC/RN (257,262,264–268). LC and RN can influence the OFC 
directly through the noradrenergic and serotonergic pathways respectively 
(257,262,268). Supplementary to the OT, the OFC is also susceptible to VNS. VNS 
could also stimulate the NTS-LC/RN-OFC pathways (137,257,262,263,265,269). 
Furthermore, LC can also act on the basolateral nucleus of the amygdala and/or 
paraventricular nucleus (PVN) of the hypothalamus (263,269). Both of these areas acts 
on the OT (257,269). The NTS can also project directly to the PVN (hypothalamus), 
which acts on the OT (257,265,268). In summary, it is possible that olfactory structures 
such as the OT, OB and OFC could be modulated through serotonergic, noradrenergic, 
cholinergic and dopaminergic pathways through non-invasive, auricular VNS (Figure 
4.1). 
 
The NTS play an integral role to convey the neuromodulatory effects of the AbVN 
(137,138). The links between the NTS and OT has been supported by several studies, 
which observed the responses of OB from the OT when stimulation is provided on the 
sensory vagus (1,20,21). In summary, due to the numerous interconnections of the OT 
mentioned in the previous text, it can be considered that OT plays a key role in state-
dependent olfactory processing, which can be modulated with auricular VNS (257) 
(Figure 4.1). It is also necessary to mention that separate nerves to the VN (trigeminal 
and facial nerves) have the potential to modulate the NTS and subsequently, the 
olfactory system and related olfactory function (270). As detailed in Figure 1.6B, in 
addition to the auricular VN, the facial and trigeminal nerves are also distributed in the 
stimulation area of the electrodes in Experiment 2 (271). Therefore, all of these nerves 
could be stimulated with the electrical stimulation (TENS) in Experiment 2 and 
therefore the potential contribution of all of these nerves cannot be excluded to the 






Figure 4.1. The pathway of auricular VN to the olfactory centres.  
Coloured arrows indicate the type of pathways in corresponding texts given. Figure is 
associated with Chapter 4.3 in the current thesis. Label in image: NTS = Nucleus 
Tractus Solitarius. Retrieved from Maharjan et al., (244). 
 
 
4.4 Median nerve and its potential connections with the 
olfactory networks 
 
Exploration of the neurocircuitry in the wake of indirect VNS through non-invasive 
MNS is central to understanding the potential pathways in, which electrostimulation of 
the MN could potentially influence olfactory function. In the present literature, three 
potential pathways have been proposed by, which neuromodulation of the MN could 
influence olfactory regions in the cortex. This includes indirect stimulation of the VN 
through the NTS to the olfactory regions, stimulation of the DMV, improving gastric 
mobility and its subsequent effects on the insula-olfactory regions of the cortex and 
MNS effects on odour image presentation in the OFC. 
 
In current literature, the NTS is considered a hub of neuroanatomical intersection centre 
for pathways associated with the peripheral and cranial nerves distributed to the scalp, 
face, auricular and body (138,196,272). Furthermore, the hub of NTS for the peripheral 
and cranial nerve stimulation suggests that indirect stimulation of the VN (using MNS) 
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influences a similar neural network (including NTS) to that of direct VNS (138). MNS 
reaches the NTS (19,138,156,160,163,168,169) and can influence the OT, OFC and OB 
via the LC, RN or/and the insula (in the same manner as mentioned in the previous 
chapter) (Figure 4.2). 
 
In addition to the aforementioned neurocircuitry, past literature using fMRI has also 
indicated that low frequency MNS (in comparison to placebo) can lead to stronger 
deactivation on hippocampal formation (273). The hippocampal formation is 
understood to be organised as a unidirectional circuit, made up of the EC, dentate gyrus, 
CA1 and CA3 subfields and the subiculum (274). The EC is also understood in past 
literature to serve as a gateway into the hippocampal formation, receiving monosynaptic 
inputs from numerous regions, particularly the amygdala and olfactory cortices in the 
context of olfactory processing (274). This is another potential pathway that allows 
MNS to exert its effects to the olfactory regions, however previous literature has not 
indicated a direct route from the MN to the EC. One potential route could be through 
the NTS (VN brainstem nuclei) as previously mentioned, as it is considered the 
neuroanatomical intersection centre for pathways associated with peripheral nerves at 
the level of the brainstem (138,196,272). 
 
As mentioned previously, the NTS conveys neuromodulatory effects of the MN through 
its interactions with the dorsal vagal complex [specifically the DMV (21,138,163)]. The 
dorsal vagal complex receives a large number of afferent axons from the VN that 
convey information regarding cardiovascular, respiratory and gastrointestinal sensory 
systems (138,275,276). This pathway also conveys MNS (indirect VNS) to enhance 
gastric mobility (12,14,15,17) and reduce symptoms of nausea and vomiting (11,13,16). 
In a previous study (196), sensitive anterograde tracer was used to trace connections of 
the NTS within the brain. It was revealed that these sites included the dorsal vagal 
complex, nucleus gracilis, parasolitary, dorsomotor and hypoglossal nuclei, thalamus 
(NPvt), hypothalamus and the OT (196). Additionally, all of these aforementioned 




MNS (indirect VNS) that reaches the DMV is associated with improving gastric 
functions (11,14,163,277–280,15–19,154,156,160). These vagal afferents from the 
gastrointestinal tract project back to the NTS (196,250) (Figure 4.2), which is integrated 
in the parabrachial nucleus, where this control of behavioural function is projected to 
the hypothalamus and amygdala (250). The control of gastric homeostasis of the body is 
projected to the ventral and dorsal portions of the anterior insula (250) through the 
thalamus (196). Specifically, the visceral and sensory input is represented in the mid-
posterior aspects of the insula while olfactory and gustatory stimuli are represented in 
the anterior-mid insula, respectively. The projections mentioned above are also 
supported by intra-operative electrical stimulation studies (250). The insula also 
receives projections from the primary olfactory regions, OB, OFC, S-I and S-II 
(250,281), in addition to sharing reciprocal projections with the OFC (29,53) and S-I/S-
II (281) (Figure 4.2). 
 
Unlike the conscious images that we perceive through the visual system, odour patterns 
that arise from the OB are thought to present unconscious odour images. These 
unconscious odour images are associated with pattern recognition due to its complexity 
and irregularity. Unlike other senses such as vision, perception of smell is heavily 
influenced by multi-sensory inputs and our ability to detect odours arise from the sub 
modalities of the somatosensory system (55). Unlike the process of vision, when a smell 
is perceived in the environment, the spatial image of an odour from the OB is an 
unconscious one and is thought to reflect the bypass in connection to the thalamus in the 
human olfactory pathway (55). The MN is involved in a plethora of effects of, which 
the most prominent being a representor of sensory sensation of touch through the 
activation of the S-I, S-II and SMA (141–144). It is suggested that when an odour image 
is perceived through the orthonasal pathway, it travels to the S-I/S-II/SMA, which then 
connects to the OFC (55). Due to the activation of these somatosensory areas of the 
cortex (S-I, S-II, SMA), there is potential that MNS could strengthen the odour image 
presentation to the OFC through the increased activation of the S-I/S-II/SMA. This 
needs to be investigated using a combination of olfactory functional tests in conjunction 






Figure 4.2. The potential pathways to the olfactory network via MNS. 
Figure legend in the image indicates the type of pathways (presented by different 
colours in the image) and all abbreviations used in the image. Structures in colour blue 
refer to the indirect pathway of VNS (median nerve stimulation) to the olfactory 
network while structures in colour green refer to the stimulation of the NTS with the 
DMV (VN brainstem nucleus) and subsequent interactions with the insula to the 
olfactory network. Orange structures represent the structures of the main olfactory 
system. Numbers on the pathways indicate references in the current thesis. 




In summary, although there is evidence in the existing literature (the three potential 
pathways indicated in this chapter) that there are solid neural networks in between the 
MN and the olfactory system, the present study (Experiment 1) could not alter the OTT 
performance in healthy cohorts. However, potential effects of MNS on STT 
performance (higher-order olfactory function), in comparison to lower-order olfactory 
measure of OTT (74,76) in healthy cohorts still need to be investigated in future studies. 
In addition, potential effects of MNS on OTT and STT performances on patients with 






4.4 Exploration of the primary communication centre of the 
olfactory cortex (orbitofrontal cortex) using near-infrared 
spectroscopy during olfactory function 
 
The use of functional imaging techniques, alongside neuromodulation and olfactory 
testing is a crucial step towards understanding the effects of neuromodulation on the 
olfactory system. In the current study, NIRS was used to observe the effects of direct 
auricular VNS on both hemispheres of the OFC (Experiment 2). In past literature, 
studies using PET and fMRI techniques have indicated that passive smelling of odours 
can activate the amygdala-PC, OFC and the insular-peri-insular cortex (52). Although it 
is a part of the secondary olfaction regions, the OFC is understood to be the main 
communication station of olfaction in the cortex (29,30). It is involved in multiple 
complex sensory pathways that provide input from most of the major sensory and 
limbic structures, highlighting its role in multisensory integration (27,29,282). 
 
In an article by Savic & colleagues (52) investigations using PET into cortical regions 
that are activated during different olfactory testing tasks (smelling of passive odourless 
air, single odours, ODT, odour quality and ORT) were recorded. It was indicated that 
passive smelling of odours can activate the amygdala-PC, insular cortex, right 
hemisphere of the OFC, thalamus and cingulate cortex (157,220,221,283). In a recent 
meta-analysis and review (130), it was reported that patients with PD presented a 
significantly larger OB volume on the right hemisphere, indicating the presence of 
lateralised differences between the two hemispheres. In support, several articles have 
indicated that the right hemisphere is more important for higher-order processing of 
smell sensation that the left hemisphere (157,284,285). Functional imaging studies 
attribute the right-side lateralised differences to odours inducing increased activation 
within the right PC and OFC, which are core anatomical structures in olfactory 
processing (157). There are also reports that support the notion that right-side 
dominance is only present when discriminating unfamiliar odours but this effect 
disappears when the odours are familiar (52). In human studies, use of fMRI studies 
have also demonstrated that smelling produces an increase in cerebral blood flow at the 
junction of the inferior frontal-temporal lobes and the right OFC (212,216). Numerous 
reports using fMRI techniques also indicate a right-hemisphere dominance in OFC 
activation under odour judgement tasks (50,213,216–220).  
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Previous studies using functional brain imaging techniques have reported that direct, 
invasive VNS of 20-30 Hz caused significant increases in blood flow in the bilateral 
OFC and right EC, which did not occur under 1 Hz. Stimulation of 1-30 Hz however, 
share similar increased neural activation patterns in the right thalamus, right postcentral 
gyrus, bilateral (inferior) cerebellum, amygdala, hippocampus and posterior cingulate 
gyrus (286–289). In comparison to past literature on direct invasive VNS using 20-30 
Hz, (8,23,137,286–289) but in support of direct invasive VNS using 1 Hz (286,289), 
Experiment 2 in the current study did not display any significant effects under direct 
non-invasive auricular VNS using 10 Hz in the OFC. In contrast, direct non-invasive 
auricular VNS under high frequency (80 Hz) displayed significant differences in the 
contralateral-right hemispheric OFC. In summary, the spectrum of different frequencies 
of direct VNS results in distinguishable effects on the OFC, with 1-10 Hz exhibiting no 
effect on either hemisphere of the brain, 20-30 Hz depicting bilateral OFC activation 
and 80 Hz presenting contralateral OFC activation. Further exploration of the spectrum 
of different frequencies could be pivotal in understanding why only certain frequencies 
are able to enhance STT performance (non-invasive, direct auricular VNS of 80 Hz) in 
comparison to non-invasive, direct auricular VNS using low frequency of 10 Hz.  
 
In comparison to the spectrum of different frequencies using direct VNS explored in the 
context of cortical activation, the scope of cortical activation using MNS in the present 
literature has largely focused on S-I and S-II (11,142,144). In these studies, MNS under 
low frequencies (0.5-2.0 Hz) were indicated to present maximal activation of the S-I 
and S-II. MNS of 5 Hz resulted in an absence of activation in the S-I, while the use of 
15-30 Hz MNS only had effects on some of the participants in the enrolled study (290). 
The use of MNS in higher frequencies (50 Hz) was also explored in one study and 
resulted in a reduced activation of the S-I in comparison to the aforementioned lower 
frequencies of MNS (144). Separate studies also reported that the use of low frequency 
MNS using 1.5-4 Hz, which displayed increased cortical activation of S-I in comparison 
to the use MNS of frequencies higher than 4 Hz, in animals models (291) and humans 
studies (292). Furthermore, previous studies have also reported the use of low 
frequencies MNS of 10-25 Hz on the modulation of improving gastric function 
(15,17,19,163). In summary, these reports indicate a lack of exploration of the MN 
under high frequencies, potentially due to the initial findings of 50 Hz for S-I activation 
being less effective in cortical activation in comparison to the lower frequencies.  
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4.5 Clinical implications of VN neuromodulation  
 
Loss of olfactory function is very common in neurodegenerative diseases, which 
includes AD, PD, vascular dementia, frontotemporal dementia (36), Huntington’s 
Chorea (38,127), alcoholic Korsakoff’s syndrome (293,294), Pick’s disease (38) and 
amyotrophic lateral sclerosis (38,295). Olfactory impairment in AD and PD is one of the 
earliest symptoms and is recognised as a pre-mediator of future pathology in these 
neurodegenerative diseases. Both of these diseases (AD and PD) present olfactory 
impairments in over 90% of the patients, with a higher incidence in men (34,36,37). It is 
also indicated in past literature that olfactory impairments in these conditions could 
potentially affect separate symptomology of the neurodegenerative diseases. Therefore, 
this stresses the need to investigate the potential treatment options in olfactory 
dysfunction in these diseases (36).  
 
Several issues highlight the necessity to investigate olfactory impairments in 
neurodegenerative diseases. This includes preclinical diagnosis, safety and quality of 
life concerns (reduced detection of toxic odorants, inadequate nutritional intake and 
diminished ability to experience pleasure in the context of eating) (38). Other potential 
issues include the contribution of the olfactory pathways in the pathogenesis of 
neurodegenerative diseases, link between the pre-symptomatic olfactory disturbance 
and genetic markers and similarities between neuroanatomical substrates and 
pathological mechanisms (38). In addition to being an impairment present from the 
early stages of neurodegenerative diseases such as AD and PD (34,38,41,296), olfactory 
dysfunction present in neurodegenerative diseases can help differentiate certain 
conditions. Olfactory impairments can be used to differentiate PD from 
neurodegenerative conditions that resemble PD such as progressive supranuclear palsy 
(121,122), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism (67), 
multiple system atrophy (122,123), corticobasal degeneration (122) and essential tremor 
(124,125). Olfactory symptoms also appear alongside non-motor symptoms related to 
PD pathology, such as autonomic (cardiovascular) and rapid eye movement-sleep 




It has also been indicated in the current literature that higher the olfactory dysfunction is 
at baseline in patients diagnosed with PD, the higher the risk of developing visual 
hallucinations and greater cognitive dysfunction (34). As indicated in Figure 1.4 and 
previous articles by Braak & colleagues (128,133), the initial spread of PD pathology 
(LN) originates at the DMV due to the vulnerability of long unmyelinated projection 
cells of this nuclei. In addition, the spread of pathology in the early stages of PD is 
present in the OB and anterior olfactory nucleus (34,133). This is followed by the 
presence of PD pathology in the OT, PC, periamygdaloid cortex and EC (133). This 
supports the presence of olfactory impairments in the earliest stages of PD (preceding 
the motor symptoms).  
 
A recent article by Doty & colleagues (91) reported that patients with PD had reduced 
performance in STT in comparison to healthy controls. In Experiment 2, healthy 
participants displayed an improvement in STT performance using direct, auricular high 
frequency VNS. Significant improvements in clinical PD motor symptoms have also 
been associated with direct, high frequency (130 Hz) auricular VNS (177). It has been 
indicated that deficits of olfactory functions are associated with the beginning of 
symptomology separate to olfaction in neurodegenerative diseases (36). Therefore, this 
suggests that potential benefits could also extend past solely olfaction if potential 
amelioration of olfactory impairments were possible.  
 
Comprehension of the mechanisms of plasticity in the olfactory system will enable 
understanding into brain mechanism for recovery and reorganisational process of the 
brain. It is also particularly relevant to the loss of olfactory function as one of the initial 
symptoms in neurodegenerative diseases (such as AD and PD) (41). Therefore, the 
potential of improving STT performance (in line with increased OFC activation) using 
non-invasive, direct high frequency VNS on olfactory function in the early stages of PD 
needs to be investigated further in future studies. This should be performed using the 
non-invasive approach as it exhibits effects similar to that of invasive approaches (137) 
but it also eliminates the risk associated with surgical implementation in invasive VNS 
approaches (192,194). To our knowledge, there has been no report of side effects due to 
non-invasive, direct or indirect (MNS) VNS in the context of cortical activity and 
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therefore, a negative effect through the use of non-invasive, direct and indirect (MNS) 
VNS would be a rare possibility in the context of previous research. 
 
The use of neuromodulation in the current experiments could also be coupled with 
olfactory training techniques (exposure to training odours twice a day, with exposure 
involving the use of one deep sniff of the odour) used in past literature (41). In an article 
by Kollndorfer & colleagues (41), an increase in OTT performance using the same 
Sniffin’ Sticks techniques of the current study was present after olfactory training 
techniques. In our experiments using non-invasive direct auricular VNS, we found 
improvements in the STT but not in OTT. There is potential to use both 
neuromodulation and olfactory training techniques, which could potentially improve 
OTT and also further improve STT performance. Resolving or potentially improving 
olfactory functions in both lower-order (OTT) and higher-order (STT) perceptual 
olfactory processing systems could be important in reducing the overall olfactory 
impairments present from early stages of AD or PD. Implementation of another duality 
of treatment methods could include the use of odour deprivation techniques (use of 
micro foam surgical tape over the nostrils to occlude nasal airflow in an odour-free, 
negative-pressure room) alongside neuromodulation. Odour deprivation techniques in 
past literature (298) had an influence on odour quality coding in the OFC. Therefore, if 
this technique was co-instilled with neuromodulation techniques used in the current 
study, it would potentially provide supplementary benefits in olfactory test performance 
to that of VNS. 
 
 
4.6 Future studies on direct or indirect VN neuromodulation 
 
In the current study, although non-invasive approaches of indirect VNS (using MNS) 
showed no improvements in OTT performance, direct auricular high frequency VNS 
exhibited an improvement in STT performance with increased cortical activation of the 
OFC (right hemisphere). The experiments in the current study have raised several 
questions that need to be addressed with future investigations in direct and indirect 
stimulation of the VN. In this chapter, future research ideas are discussed in conjunction 
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with how these investigations would aid in further understanding of the results from the 
current thesis. 
 
One major recurring theme from the results of the current study is the need to explore 
the full spectrum of high and low frequencies using direct (non-invasive auricular VNS) 
and indirect (non-invasive MNS) VNS. The only effects on olfactory processing (STT 
performance and OFC activation in the right hemisphere) were present under direct 
auricular high frequency VNS. As mentioned in the previous chapters of the thesis, 
although the exploration of stimulations under low frequencies is abundant in both VN 
(8,23,137,286–289) and MN (17,19,144,163,290–292), there is a lack of exploration of 
the higher frequencies of both direct and indirect (through MNS) VNS in human 
studies. Future research using non-invasive VNS under high frequencies of 80 Hz or 
over should be explored using similar experimental parameters to the current studies. 
Such exploration has been previously demonstrated for the lower frequencies in both 
the direct and indirect VNS approaches. In particular, it is indicated that small changes 
of Hz (1.5-4 Hz in comparison to over 5-25 Hz) under low frequency stimulation of the 
MN has significant differences in cortical activation of S-I (144,291,292) while use of 1 
Hz in comparison to 10 Hz in VNS had different regions of activation in the cortex 
(8,286–288). These previous studies indicate the importance of exploring small changes 
in frequencies of stimulation in conjunction to observing the full spectrum of high 
frequency stimulation using direct and indirect VNS, to encapsulate the range of effects 
in cortical activation, previously explored for direct and indirect VNS under low 
frequencies.  
 
To date, there are no studies that have explored the complete pathways from the direct 
or indirect VNS to the cortical representors of olfactory functions. This indicates a lack 
of knowledge that should be addressed in future research as more than three decades 
ago, past research in animal studies have alluded to the effects of direct VNS in 
modulating the activity of the OB (1,20). Particularly on indirect VNS (MNS), several 
studies in existing literature have attempted to propose potential pathways from MNS 
(indirect VNS) to the VN brainstem nuclei (NTS) (Figure 4.2). In particular, Songzi & 
colleagues (156) have previously stated that the MN could exert its effects to the NTS 
through the spinal cord (C3-T3 section), while another article by Imai & colleagues 
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(163) suggested that spinal nerves can contribute to gastric function through the NTS 
(VN brainstem nuclei). However, these studies do not indicate any effects of the indirect 
VNS to the areas of cortex responsible for olfactory functions. Therefore, future 
research is required, particularly using fMRI techniques, which would allow the 
complete exploration of the cortex under neuromodulation (direct and indirect 
approaches) of VNS. These explorations would legitimise the full neurocircuitry of the 
direct and indirect VNS to all potential connections in the olfactory regions of the 
cortex, and also provide support to the neurocircuits that were presented for both direct 
(Figure 4.1) and indirect (Figure 4.2) VNS in the current studies. 
 
One future study that should also be addressed is to observe the effects of non-invasive, 
indirect VNS (using MNS) on STT performance. As non-invasive, direct auricular VNS 
exhibited improvements in STT performance in the current study, these effects could be 
replicated with indirect VNS (using MNS). This would further support existing 
literature that the MN is an indirect stimulation of the VN (10–15,17). Separate 
olfactory testing modalities to OTT and STT that includes ODT, OIT, OMT and ORT 
still need to be investigated under direct and indirect VNS under high and low 
frequencies. This would help answer questions as to whether neuromodulation of these 
nerves is effective for the full array of olfactory functions. This would also aid in 
composing a comprehensive map of the cortex that could detail, which parts of the 
cortex are activated by certain neuromodulatory techniques (direct or indirect VNS). It 
could also aid in understanding which combination of cortical structures is responsible 
for the processing of each olfactory testing modality. A particular neuroimaging 
technique such as a fMRI would allow the observation of the whole cortex in 
combination with neuromodulatory techniques. A previous fMRI study with low 
frequency, direct auricular VNS has already demonstrated alterations of numerous 
different brain regions (137). Therefore, using fMRI to observe primary and secondary 
olfactory regions in conjunction with olfactory testing and neuromodulation (direct and 
indirect VNS) is the next step in future investigations.  
 
In existing literature, direct VNS is currently available as a potential therapy for 
intractable/medically refractory epilepsy (9,138,184,185), chronic treatment-resistant 
depression (186), pain (186,187), primary headaches and medication-overuse headaches 
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(188). Despite the fact that the first presence of PD-pathology (LN) is present in the 
DMV (128) and olfactory impairments precede motor symptoms in PD (34), there is no 
existing literature on the use of direct VNS as potential treatment for olfactory 
impairments in humans. Our current study (Experiment 2) was the first to indicate that 
neuromodulation of non-invasive, direct auricular high frequency VNS can improve 
STT performance (with supplementary increase in cortical activation on the OFC-right 
hemisphere). This therefore, indicated the need for future research to investigate the 
potential of direct VNS in improving other olfactory tests that are also impaired in 
patients with PD (ODT/OIT/ORT) (69,73,106,124,126,127). Furthermore, this study 
only investigated the use of acute VNS. Investigations into the use of chronic VNS 
under the same stimulation parameters (high and low frequencies) to the current study 
in the performance of olfactory tests should also be explored. 
 
Although standard methods were used to measure OTT and STT in the current study, 
there are numerous approaches in olfactory behavioural tasks that are available to test 
these functions. Replicating the current experiments using different methodologies to 
test OTT and STT would enable more validity in the results of the current study and 
should be explored in future investigations. In addition, the exploration of olfactory 
function was performed in healthy participants in the current study. As these 
participants presented healthy responses in ODMT, OIT and OTT (65), future studies 
should observe the effects of nerve neuromodulation on participants who have 
impairments in olfactory function prior to the stimulation. Population groups that could 
be used in future studies that replicate the current study could include patients with AD 
or PD as they present olfactory impairments from the early stages of respective 
conditions (34,36,38).  
 
In Experiment 2, there were eighteen participants in a within-subject design under three 
stimulation parameters (high frequency VNS, low frequency VNS and placebo). In 
addition to presented p-values for the statistical significance, the effect size [correlation 
coefficient (r): 0.39 for the STT with the significant output after direct auricular VNS 
under high frequency stimulation] revealed a medium/moderate effect [in line with 
Cohen’s thresholds for deducing the effect size (r: 0.1 small effect, r: 0.3 moderate 
effect, r: 0.5 large effect)] (299). Furthermore, it is understood that the use of 10 mins of 
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nerve stimulation produces neuromodulatory effects for about an hour after the period 
of neurostimulation (177). However, the exact time that this effect begins to occur is 
currently unknown. If the exact time for the onset of the effect was clarified then 
performing the same experiments during the stimulation period, rather than just after the 
stimulation, could potentially result with a higher effect-size. 
 
It is also necessary to mention that the present experiments only included healthy, male 
participants of European-New Zealand descent. Only one ethnicity was used as there are 
reports of cross-cultural differences in odour perception and rating, independent of sex 
(300–302). The difficulty in enrolling female participants for the current study was due 
to the required calibration of the menstrual cycle across the female participants. Future 
studies that could examine the responses of neuromodulation on separate cohort groups 
and on female cohorts in the context of hormonal influences over the olfactory system 
would aid in the exploration of all cohorts in the population in future studies using the 





In conclusion, the current study exhibited, for the first time in human research that non-
invasive, direct auricular high frequency VNS is effective in improving the healthy, 
adult, male olfactory function in the STT, accompanied by increased activation of the 
right hemispheric OFC. In comparison, non-invasive, indirect VNS (using MNS) did 
not improve the performance of OTT for the healthy, adult, male participants. As 
olfactory dysfunction is an early and crucial symptom present in neurological diseases 
such as AD and PD and also in the context of STT impairment in PD, a potential chance 
to ameliorate such deficits could be essential in early treatment processes. Future 
research needs to incorporate, as this current study has, direct and indirect, non-invasive 
VNS with functional imaging of all relevant olfactory regions in the cortex, to gain a 
complete representation of the cortical structures influenced by neuromodulation of 






1.  García-Díaz DE, Aguilar-Baturoni HU, Guevara-Aguilar R, Wayner MJ. Vagus 
nerve stimulation modifies the electrical activity of the olfactory bulb. Brain Res 
Bull. 1984;12(5):529–37.  
2.  Cain WS, Murphy CL. Interaction between chemoreceptive modalities of odour 
and irritation. Nature. 1980;284(5753):255–7.  
3.  Dalton P, Doolittle N, Nagata H, Breslin PAS. The merging of the senses: 
Integration of subthreshold taste and smell. Nat Neurosci. 2000;3(5):431–2.  
4.  Hummel T, Livermore A. Intranasal chemosensory function of the trigeminal 
nerve and aspects of its relation to olfaction. Int Arch Occup Environ Health. 
2002;75(5):305–13.  
5.  Katz DB, Nicolelis MAL, Simon SA. Nutrient Tasting and Signaling 
Mechanisms in the Gut IV. There is more to taste than meets the tongue. Am J 
Physiol Gastrointest Liver Physiol. 2000;278:G6–9.  
6.  Kobal G, Hummel C. Cerebral chemosensory evoked potentials elicited by 
chemical stimulation of the human olfactory and respiratory nasal mucosa. 
Electroencephalogr Clin Neurophysiol Evoked Potentials. 1988;71(4):241–50.  
7.  Schaefer ML, Bottger B, Silver WL, Finger TE. Trigeminal Collaterals in the 
Nasal Epithelium and Olfactory Bulb : A Potential Route for Direct Modulation 
of Olfactory Information by Trigeminal Stimuli. J Comp Neurol. 2002;444:221–
6.  
8.  Kirchner A, Landis BN, Haslbeck M, Stefan H, Renner B, Hummel T. 
Chemosensory function in patients with vagal nerve stimulators. J Clin 
Neurophysiol. 2004;21(6):418–25.  
9.  Yuan H, Silberstein SD. Vagus Nerve and Vagus Nerve Stimulation, a 
Comprehensive Review: Part II. Headache. 2016;56(2):259–66.  
10.  Lee A, Fan LTY. Stimulation of the wrist acupuncture point PCPostoperative 
Nausea and Vomiting. Cochrane Database Syst Rev 2015,. 2011;(11):4–7.  
11.  Zotelli VLR, Grillio CM, Rosario de Sousa M da L. Nausea Control by Needling 
at Acupuncture Point Neiguan ( PC6 ) During an Intraoral Impression-Taking 
Procedure. J Acupunct Meridian Stud. 2014;7(6):318–23.  
12.  Tatewaki M, Strickland C, Fukuda H, Tsuchida D, Hoshino E, Pappas TN, et al. 
Effects of acupuncture on vasopressin-induced emesis in conscious dogs. Am J 
Physiol Integr Comp Physiol. 2005;288(2):401–8.  
13.  Bai L, Yan H, Li N, Qin W, Chen P, Liu P, et al. Neural specificity of 
acupuncture stimulation at pericardium 6: Evidence from an fMRI study. J Magn 
Reson Imaging. 2010;31(1):71–7.  
14.  Chen JDZ, Qian L, Ouyang H, Yin J. Gastric electrical stimulation with short 
pulses reduces vomiting but not dysrhythmias in dogs. Gastroenterology. 
2003;124(2):401–9.  
15.  Xu S, Hou X, Zha H, Gao Z, Chen Y, Zhang JDZ. Electroacupuncture 
71 
 
Accelerates Solid Gastric Emptying and Improves Dyspeptic Symptoms in 
Patients with Functional Dyspepsia. Dig Dis Sci. 2006;51(12):2154–9.  
16.  Takahashi T. Mechanism of Acupuncture on Neuromodulation in the Gut — A 
Review. Neuromodulation. 2011;14:8–12.  
17.  Ouyang HUI, Yin J, Wang Z, Pasricha PJ, Chen JDZ, Yin J, et al. 
Electroacupuncture accelerates gastric emptying in association with changes in 
vagal activity. Am J Gastrointest Liver Physiol. 2002;282:390–6.  
18.  Berthoud HR, Neuhuber WL. Functional and chemical anatomy of the afferent 
vagal system. Auton Neurosci Basic Clin. 2000;85(1–3):1–17.  
19.  Noguchi E, Hayashi H. Increases in gastric acidity in response to EA stimulation 
of hindlimb of anesthetized rats. Jpn J Physiol. 1996;46:53–8.  
20.  Garcia-Diaz DE, Aguilar-Baturoni HU, Guevara-Aguilar R. Olfactory Bulb 
Neurons Respond to Gastric Distension. Brain Res Bull. 1985;15(1):661–4.  
21.  Ruggiero DA, Anwar S, Kim J, Glickstein SB. Visceral afferent pathways to the 
thalamus and olfactory tubercle: Behavioral Implications. Brain Res. 
1998;799(1):159–71.  
22.  Val-Laillet D, Biraben A, Randuineau G, Malbert CH. Chronic vagus nerve 
stimulation decreased weight gain, food consumption and sweet craving in adult 
obese minipigs. Appetite. 2010;55(2):245–52  
23.  Sperling, W., Biermann, T., Spannenberger, R., Clepce, M., Padberg, F., 
Reulbach U et al. Changes in gustatory perceptions of patients with major 
depression treated with vagus nerve stimulation (VNS). Pharmacopsychiatry. 
2011;44(02):67–71.  
24.  Arruda D, Publio R, Roque AC. The Periglomerular Cell of the Olfactory Bulb 
and its Role in Controlling Mitral Cell Spiking: A Computational Model. PLoS 
One. 2013;8(2).  
25.  Katata K, Sakai N, Doi K, Kawamitsu H, Fujii M, Sugimura K, et al. Functional 
MRI of regional brain responses to ‘pleasant’and ‘unpleasant’odors. Acta 
Otolaryngol. 2009;129 (sup56:85–90.  
26.  Kovacs T. Mechanisms of olfactory dysfunction in aging and neurodegenerative 
disorders. Ageing Res Rev. 2004;3(2):215–32.  
27.  Rolls ET, Kringelbach ML, De Araujo IET. Different representations of pleasant 
and unpleasant odours in the human brain. Eur J Neurosci. 2003;18:695–703.  
28.  Sobel N, Johnson B, Mainland J, Yousem D. Functional neuroimaging of human 
olfaction. Neurol Dis Ther. 2003;57:251–74.  
29.  Gottfried JA. Smell: central nervous processing. In: Hummel T, Welge-Lussen 
A, editors. Taste and smell. Karger Publishers; 2006. p. 44–69.  
30.  Patel RM, Pinto JM. Olfaction : Anatomy , Physiology , and Disease. 
Otolaryngol Neck Surg. 2014;60(October 2013):54–60.  
31.  Harada H, Tanaka M, Kato T. Brain olfactory activation measured by near-
infrared spectroscopy in humans. J Laryngol Otol. 2006;120(08):638–43. 
32.  Ishimaru T, Yata T, Horikawa K, Hatanaka S. Near-infrared spectroscopy of the 
72 
 
adult human olfactory cortex. Acta Otolaryngol Suppl. 2004;6489(553):95–8. 
33.  Kobayashi E, Karaki M, Touge T, Deguchi K, Ikeda K, Mori N, et al. Olfactory 
assessment using near-infrared spectroscopy. 2012 ICME Int Conf Complex Med 
Eng. 2012;517–20.  
34.  Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol. 
2012;8(6):329–39.  
35.  Wesson DW, Levy E, Nixon RA, Wilson DA. Olfactory dysfunction Correlates 
with Amyloid-B Burden in an Alzheimer’s Disease Mouse Model. J Neurosci. 
2010;30(2):505–14.  
36.  Alves J, Petrosyan A, Magalhaes R. Olfactory dysfunction in dementia. World J 
Clin Cases. 2014;2(11):661–9.  
37.  Duff K, Mccaffrey RJ, Solomon GS. Test : Successfully Discriminating Probable 
and Major Depression. J Neuropsychiatr. 2002;14(2):197–201.  
38.  Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in Neurodegenerative 
Disease. Arch Neurol. 1998;55(1):84.  
39.  Gazzaniga MS, Ivry RB, Mangun GR. Cognitive Neuroscience: The biology of 
the mind. 4th Editio. New York: W. W. Norton & Company, Inc.; 2014. 172-175 
p.  
40.  Huart C, Rombaux P, Hummel T. Plasticity of the human olfactory system: The 
olfactory bulb. Molecules. 2013;18(9):11586–600.  
41.  Kollndorfer K, Kowalczyk K, Hoche E, Mueller CA, Pollak M, Trattnig S, et al. 
Recovery of olfactory function induces neuroplasticity effects in patients with 
smell loss. Neural Plast. 2014;2014.  
42.  Mainland K, Kowalczyk K, Hoche E, Mueller CA, M P, S T, et al. Olfactory 
plasticity: one nostril knows what the other learns. Nature. 2002;419(6909):802–
802.  
43.  Wilson DA, Best AR, Sullivan RM. Plasticity in the olfactory system: lessons for 
the neurobiology of memory. Neurosci. 2004;10(6):513–24.  
44.  Mason RT, LeMaster MP, Muller-Schwarze D. Vomeronasal systems and main 
olfactory systems. In: Chemical signals in vertebrates 10. 10th Editi. New York: 
Springer Science & Business Media; 2003. p. 216–99.  
45.  Cleland TA, Linster C. Central olfactory processing. In: Dekker M, editor. 
Handbook of Olfaction and Gustation. 2nd Editio. New York; 2003. p. 165–80.  
46.  Halpern M, Martinez-Marcos A. Structure and function of the vomeronasal 
system: an update. Prog Neurobiol. 2003;70:245–318.  
47.  Halpern M, Kubie JL. Chemical access to the vomeronasal organs of garter 
snakes. Physiol Behav. 1980;24:367–71.  
48.  Sobel N, Prabhakaran V, Zhao ZUO, Desmond JE, Glover GH, Sullivan E V, et 
al. Time Course of Odorant-Induced Activation in the Human Primary Olfactory 
Cortex. J Neurophysiol. 2000;83:537–51.  
49.  Wilson DA, Xu W, Sadrian B, Courtiol E, Cohen Y, Barnes DC. Cortical odor 
processing in health and disease. Prog Brain Res. 2014;208:275–305.  
73 
 
50.  Buck L, Axel R. A novel multigene family may encode odorant receptors: A 
molecular basis for odor recognition. Cell. 1991;65(1):175–87.  
51.  Powell TPS, Cowan WM, Raisman G. The central olfactory connexions. J Anat. 
1965;99(Pt 4):791–813.  
52.  Savic I, Gulyas B, Larsson M, Roland P. Olfactory Functions Are Mediated by 
Parallel and Hierarchical Processing. Neuron. 2000;26:735–45.  
53.  Rolls ET, Critchley HD, Mason R, Wakeman EA. Orbitofrontal Cortex Neurons : 
Role in Olfactory and Visual Association Learning. J Neurophysiol. 
1996;75(5):1970–81.  
54.  Kandel ER. Principles of Neural Science. 4th ed. McGraw-Hill; 2000. 1-1414 p.  
55.  Shepherd GM. Smell images and the flavour system in the human brain. Nature. 
2006;444(16 Nov):316–21.  
56.  Shepherd GM. The Human Sense of Smell: Are We Better Than We Think? 
PLoS Biol. 2004;2(5):572–5.  
57.  Patton KT, Thibodeau GA. Anatomy & Physiology. 9th Editio. 2015. 550-590 p.  
58.  Synder DJ, Bartoshuk LM. Epidemiological studies of taste function: Discussion 
and perspectives. Ann N Y Acad Sci. 2010;1170(1):574–80.  
59.  Tubaldi F, Ansuini C, Tirindelli R, Castiello U. The Grasping Side of Odours. 
PLoS One. 2008;3(3):e1795.  
60.  Wedekind C, Seebeck T, Bettens F, Paepke AJ. MHC-Dependent Mate 
Preferences in Humans. Proc R Soc B Biol Sci. 1995;260(1359):245–9.  
61.  Leon EA, Catalanotto FA, Werning JW. Retronasal and Orthonasal Olfactory 
Ability After Laryngectomy. Arch Otolaryngol Head Neck Surg. 2007;133:32–6.  
62.  Bult JHF, de Wijk RA, Hummel T. Investigations on multimodal sensory 
integration: Texture, taste, and ortho- and retronasal olfactory stimuli in concert. 
Neurosci Lett. 2007;411:6–10.  
63.  Small DM, Gerber JC, Mak E, Hummel T. Differential Neural Responses Evoked 
by Orthonasal versus Retronasal Odorant Perception in Humans. Neuron. 
2005;47(4):593–605.  
64.  Doty R, Shaman P, Applebaum S, Giberson R, Siksorski L, Rosenberg L. Smell 
identification ability: changes with age. Science (80- ) .1984;226(4681):1441–3. 
65.  Doty RL, McKeown DA, Lee WW, Shaman P. A study of the test-retest 
reliability of 10 olfactory tests. Chem Senses. 1995;20(6):645–56.  
66.  Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania 
Smell Identification Test: a rapid quantitative olfactory function test for the 
clinic. Physiol Behav. 1984;32:489–502.  
67.  Doty RL, Singh A, Tetrud J, Langston JW. Lack of Major Olfactory Dvsfunction 
in MPTP-Induced Parkinsonism. Annu Neurol. 1992;32:97–100.  
68.  Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. ’ Sniffin ’ Sticks ’: 
Olfactory Performance Assessed by the Combined Testing of Odor Identification 
, Odor Discrimination and Olfactory Threshold. 1997;22(1):39–52.  
74 
 
69.  Kesslak JP, Cotman CW, Chui HC, Van Den Noort S, Fang H, Pfeffer R, et al. 
Olfactory tests as possible probes for detecting and monitoring Alzheimer’s 
disease. Neurobiol Aging. 1988;9(C):399–403.  
70.  Rezek DL. Olfactory deficits as a neurologic sign in dementia of the Alzheimer 
type. Arch Neurol. 1987;44(10):1030–2.  
71.  Rumeau C, Nguyen DT, Jankowski R. How to assess olfactory performance with 
the Sniffin’ Sticks test®. Eur Ann Otorhinolaryngol Head Neck Dis. 
2016;133:203–6.  
72.  Serby M, Larson P, Kalkstein D. The Nature and Course of Olfactory Deficits in 
Alzheimer ’ s Disease. Am J Psychiatry. 1991;148(3):357–60.  
73.  Zucco GM, Zaglis D. Olfactory deficits in elderly subjects and Parkinson 
patients. Percept Mot Skills. 1991;73(1):895–8.  
74.  Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T. Cognitive factors in 
odor detection, odor discrimination, and odor identification tasks. J Clin Exp 
Neuropsychol. 2010;32(10):1062–7.  
75.  Larsson M, Semb H, Winblad B, Amberla K, Wahlund LO, Backman L. Odor 
identification in normal aging and early Alzheimer’s disease: effects of retrieval 
support. Neuropsychology. 1999;13(1):47–53.  
76.  Haehner A, Rodewald A, Gerber JC, Hummel T. Correlation of olfactory 
function with changes in the volume of the human olfactory bulb. Arch 
Otolaryngol Head Neck Surg. 2008;134(6):621–4.  
77.  Marks LE, Borg G, Ljunggren G. Individual differences in perceived exertion 
assessed by two new methods. Percept Psychophys. 1983;34(3):280–8.  
78.  Green BG, Shaffer GS, Gilmore MM. Derivation and evaluation of a semantic 
scale of oral sensation magnitude with apparent ratio properties. Chem Senses. 
1993;18(6):683–702.  
79.  Stevens SS. Mathematics, measurement, and psychophysics. In: Handbook of 
experimental psychology. Oxford, England: Wiley; 1951. p. 1–49.  
80.  Stevens SS. Psychophysics. 2nd Editio. New Jersey: Transcation Publishers; 
1975. 2-132 p.  
81.  Lawless HT, Heymann H. Sensory evaluation of food. 2nd Editio. New York: 
Springer; 2010. 1-596 p.  
82.  Bartoshuk LM. The psychophysics of taste. J Clin Nutr. 1978;31(6):1068–77.  
83.  Doty RL, Smith R, McKeown DA, Raj J. Tests of human olfactory function: 
principal components analysis suggests that most measure a common source of 
variance. Percept Psychophys. 1994;56(6):701–7.  
84.  Duffy VB, Rackstrand JR, Ferris AM. Olfactory dysfunction and related 
nutricional risk in free-living, elderly women. J Am Diet Assoc. 
1995;95(Aug):879–84.  
85.  Murphy C, Cruickshanks KJ, Klein BEK, Klein R, Nondahl DM. Prevalence of 
Olfactory Impairment. 2015;288(18):2307–12.  
86.  Schubert CR, Cruickshanks KJ, Fischer ME, Huang GH, Klein BEK, Klein R, et 
75 
 
al. Olfactory impairment in an adult population: The beaver dam offspring study. 
Chem Senses. 2012;37(4):325–34.  
87.  Stuck BA, Frey S, Freiburg C, Hörmann K, Zahnert T, Hummel T. 
Chemosensory event-related potentials in relation to side of stimulation, age, sex, 
and stimulus concentration. Clin Neurophysiol. 2006;117(6):1367–75.  
88.  Doty RL, Cameron EL. Sex differences and reproductive hormone influences on 
human odor perception. Physiol Behav. 2009;97(2):213–28.  
89.  Paik S, Lehman MN, Seiden AM, Duncan HJ, Smith D V. Human olfactory 
biopsy: the influence of age and receptor distribution. Arch Otolaryngol Neck 
Surg. 1992;118(7):731–8.  
90.  Bhatnagar KP, Kennedy RC, Baron G, Greenberg RA. Number of mitral cells 
and the bulb volume in the aging human olfactory bulb: a quantitative 
morphological study. Anat Rec. 1987;1:73–87.  
91.  Doty RL, Kamath V. The influences of age on olfaction: A review. Front 
Psychol. 2014;5(FEB):1–20.  
92.  McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et 
al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations 
from the National Institute on Aging-Alzheimer’s Association workgroups on 
diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 
2011;7(3):263–9.  
93.  Esiri MM, Wilcock GK. The olfactory bulbs in Alzheimer’s disease. J Neurol 
Neurosurg Psychiatry. 1984;47(1):56–60.  
94.  Kovács T, Cairns NJ, Lantos PL. Olfactory centres in alzheimer’s disease: 
olfactory bulb is involved in early braak’s stages. Neuroreport. 2001;12(2):285–
8.  
95.  O’Keefe J, Dostrovsky J. The hippocampus as a spatial map: Preliminary 
evidence from unit activity in the freely-moving rat. Brain Res. 1971;34(1):171–
5.  
96.  Fyhn M, Molden S, Witter MP, Moser EI, Moser MB. Spatial representation in 
the entorhinal cortex. Science (80- ). 2004;305(80):1258–64.  
97.  Kovács T, Cairns NJ, Lantos PL. ??-amyloid deposition and neurofibrillary 
tangle formation in the olfactory bulb in ageing and Alzheimer’s disease. 
Neuropathol Appl Neurobiol. 1999;25(6):481–91.  
98.  Lue L-F, Kuo Y-M, Roher AE, Brachova L, Shen Y, Sue L, et al. Lue et al 1999 
Soluble amyloidB peptide conc as a predictor of synaptic changes in alz. Am J 
Pathol. 1999;155(3):853–62.  
99.  Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. 
Correlation Between Elevated Levels of Amyloid B -Peptide in the Brain and 
Cognitive Decline. Jama. 2000;283(12):1571–7.  
100.  Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, et 
al. Amyloid-β–Associated Clinical Decline Occurs Only in the Presence of 
Elevated P-tau. Arch Neurol. 2012;69(6).  
101.  Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, et al. 
76 
 
Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in 
preclinical Alzheimer’s disease. Nat Neurosci. 2014;17(2):304–11.  
102.  Fennema-Notestine C, McEvoy LK, Hagler DJ, Jacobson MW, Dale AM. 
Structural neuroimaging in the detection and prognosis of pre-clinical and early 
AD. Behav Neurol. 2009;21(1–2):3–12.  
103.  Karow DS, McEvoy LK, Fennema-Notestine C. Relative Capability of MR 
Imaging and FDG PET to Depict Changes Associated with Purpose : Methods : 
Results : Radiology. 2010;256(3).  
104.  Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. 
Acta Neuropathol. 1991;82(4):239–59. 
105.  Fusetti, M., Fioretti, A. B., Silvagni, F., Simaskou, M., Sucapane, P., Necozione, 
S., & Eibenstein A. Smell and preclinical Alzheimer disease: study of 29 patients 
with amnesic mild cognitive impairment. J Otolaryngol Neck Surg. 
2010;39(2):175–81.  
106.  Corwin J, Serby M, Conrad P, Retrosen J. Olfactory recognition deficit in 
Alzheimer’s and Parkinsonian dementias. IRCS Med Sci Psychol Psychiatry. 
1985;  
107.  Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance 
scans for hippocampal and parahippocampal atrophy in Alzheimer’s disease. 
Neurology. 1991;41(1):51.  
108.  Knupfer L, Spiegel R. Differences in olfactory test performance between normal 
aged, Alzheimer and vascular type dementia individuals. Int J Geriatr Psychiatry. 
1986;1:3–14.  
109.  Doty RL, Reyes PF, Gregor T. Presence of both odor identification and detection 
deficits in Alzheimer’s disease. Brain ResBull. 1987;18(0361-9230):597–600.  
110.  Koss E, Weiffenbach JM, Haxby J V, Friedland RP. Olfactory detection and 
identification performance are dissociated in early Alzheimer’s disease. 
Neurology. 1988;38(8):1228–1228.  
111.  Morgan CD, Nordin S, Murphy C. Odor identification as an early marker for 
Alzheimer’s disease: impact of lexical functioning and detection sensitivity. J 
Clin Exp Neuropsychol. 1995;17(5):793–803.  
112.  Motomura N, Tomota Y. Olfactory dysfunction in dementia of Alzheimer ’ s 
type and. Psychogeriatrics. 2006;6(March):19–20.  
113.  Warner MD, Peabody CA, Flattery JJ, Tinklenberg JR. Olfactory deficits and 
Alzheimer’s disease. Biol Psychiatry. 1986;21(1):116–8.  
114.  Feldman JI, Murphy C, Davidson TM, Jalowayski AA, Jaime D, Galindo G. The 
rhinologic evaluation of Alzheimer’s disease. Laryngoscope. 
1991;101(11):1198–202.  
115.  Murphy C, Gilmore MM, Seery CS, Salmon DP, Lasker BR. Olfactory 
Thresholds Are Associated With Degree of Dementia in Alzheimer ’ s Disease. 
Neurobiol Aging. 1990;11(1):465–9.  
116.  Nordin S, Paulsen JS, Murphy C. Sensory- and memory-mediated olfactory 




117.  Hall WC. Movement and its central control. 3rd ed. Sunderland, MA, USA: 
Sinauer Asociates Inc.; 2004. Chapter 18.  
118.  Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K. 
Association of olfactory dysfunction with risk for future Parkinson’s disease. 
Ann Neurol. 2008;63(2):167–73.  
119.  Bohnen NI, Studenski SA, Constantine GM, Moore RY. Diagnostic performance 
of clinical motor and non-motor tests of Parkinson disease: A matched case-
control study. Eur J Neurol. 2008;15(7):685–91.  
120.  Deeb J, Shah M, Muhammed N, Gunasekera R, Gannon K, Findley LJ, et al. A 
basic smell test is as sensitive as a dopamine transporter scan: Comparison of 
olfaction, taste and DaTSCAN in the diagnosis of Parkinson’s disease. Qjm. 
2010;103(12):941–52.  
121.  Doty R, Golbe LI, Mckeown DA, Stern MB, Lehrach C, Crawford D. Olfactory 
testing differentiates between progressive supranuclear palsy and idiopathic 
Parkinson’s disease. Neurology. 1993;43(5):962.  
122.  Gk W, Shephard B, Hawkes C, Petruckevitch A, Lees A. Olfactory function in 
atypical par kinsonian svndromes. 1995;(14):247–50.  
123.  Goldstein DS, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y, et al. 
Biomarkers to detect central dopamine deficiency and distinguish Parkinson 
disease from multiple system atrophy. Park Relat Disord. 2008;14(8):600–7. 
124.  Busenbark KL, Huber SJ, Pahwa R, Koller WC. Olfactory function in essential 
tremor. Neurology. 1992;42(8):1631.  
125.  Shah M, Muhammed N, Findley LJ, Hawkes CH. Olfactory tests in the diagnosis 
of essential tremor. Park Relat Disord. 2008;14(7):563–8.  
126.  Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory 
dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J 
Neurol Neurosurg Psychiatry. 1992;55(2):138–42.  
127.  Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson’s disease. 
Neurology. 1983;33(7):943.  
128.  Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the 
development of Parkinson’s disease-related pathology. Cell Tissue Res. 
2004;318(1):121–34.  
129.  Braak H, Vos RAI De, Jansen ENH, Bratzke H, Braak E. Neuropathological 
hallmarks of Alzheimer ’ s and Parkinson ’ s diseases. 1998;111.  
130.  Li J, Gu CZ, Su J Bin, Zhu LH, Zhou Y, Huang HY, et al. Changes in olfactory 
bulb volume in Parkinson’s disease: A systematic review and meta-analysis. 
PLoS One. 2016;11(2):1–14.  
131.  Hopkins DA, Bieger D, deVente J, Steinbusch WM. Vagal efferent projections: 
viscerotopy, neurochemistry and effects of vagotomy. Prog Brain Res. 
1996;107:79–96.  
132.  Huang X-F, Tork I, Paxinos G. Dorsal motor nucleus of the vagus nerve: A cyto- 




133.  Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E. 
Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol 
Aging. 2003;24(2):197–211.  
134.  Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology. 
2002;59(6 Suppl 4):S3–14.  
135.  Yuan H, Silberstein SD. Vagus Nerve and Vagus Nerve Stimulation , a 
Comprehensive. J Head Face Pain. 2015;56(1):71–8.  
136.  George MS, Sackeim HA, Rush AJ, Marangell LB, Nahas Z, Husain MM, et al. 
Vagus nerve stimulation: a new tool for brain research and therapy. Biol 
Psychiatry. 2000;47(4):287–95. Available from:  
137.  Frangos E, Ellrich J, Komisaruk BR. Non-invasive access to the vagus nerve 
central projections via electrical stimulation of the external ear: FMRI evidence 
in humans. Brain Stimul. 2015;8(3):624–36. 
138.  Cakmak YO. Epilepsy, electroacupuncture and the nucleus of the solitary tract. 
Acupunct Med. 2006;24(4):164–8.  
139.  Bray GA. Afferent signals regulating food intake. Proc Nutr Soc. 
2000;59(3):373–84.  
140.  Netter FH, Brass A, Jones HR, Oppenheimer E, Forsham PH, Yonkman FF, et al. 
The Netter Collection of Medical Illustrations - Nervous, Part I - Anatomy and 
Physiology. 2001 Ed.,. Teterboro, NJ: Icon Learning Systems; 1983.  
141.  Nihashi T, Naganawa S, Sato C, Kawai H, Nakamura T. Contralateral and 
ipsilateral responses in primary somatosensory cortex following electrical median 
nerve stimulation — an fMRI study. Clin Neurophysiol. 2005;116:842–8.  
142.  Napadow V, Dhond RP, Kim J, Lacount L, Vangel M, Harris RE, et al. 
NeuroImage Brain encoding of acupuncture sensation — Coupling on-line rating 
with fMRI. Neuroimage. 2009;47(3):1055–65.  
143.  Zhang G, Yin H, Zhou Y-L, Han H-Y, Wu Y-H, Xing W, et al. Capturing 
Amplitude Changes of Low-Frequency Fluctuations in Functional Magnetic 
Resonance Imaging Signal : A Pilot Acupuncture Study on NeiGuan (PC6). J 
Altern Complement Med. 2012;18(4):387–93.  
144.  Spiegel J, Tintera J, Gawehn J, Stoeter P, Treede RD. Functional MRI of human 
primary somatosensory and motor cortex during median nerve stimulation. Clin 
Neurophysiol. 1999;110:47–52.  
145.  Takahashi T. Acupuncture for functional gastrointestinal disorders. J 
Gastroenterol. 2006;41(5):408–17.  
146.  Tillisch K. Complementary and alternative medicine for functional 
gastrointestinal disorders. Gut. 2006;55(5):593–6.  
147.  Chang X, Yan J, Lin Y, Yang R. The affects of acupuncture at sibai and neiting 
acupoints on gastric peristalsis. J Tradit Chinese Med. 2001;21(4):286–8.  
148.  Wang L. Clinical observation on acupuncture treatment in 35 cases of diabetic 
gastroparesis. J Tradit Chinese Med. 2004;24(3):163–5.  
79 
 
149.  Diehl DL. Acupuncture for gastrointestinal and hepatobiliary disorders. J Altern 
Complement Med. 1999;5(1):27–45.  
150.  Broide E, Pintov S, Portnoy S. Effectiveness of acupuncture for treatment of 
childhood constipation. Dig Dis Sci. 2001;46(6):1270–5.  
151.  Chan J, Carr I, Mayberry JF. The role of acupuncture in the treatment of irritable 
bowel syndrome: a pilot study. Hepatogastroenterology. 1997;44(17):1328–30.  
152.  Fireman Z, Segal A, Kopelman Y, Sternberg A, Carasso R. Acupuncture 
treatmentof irritable bowel syndrome. Digestion. 2001;64(2):100–3.  
153.  Schneider A, Enck P, Streitberger K, Weiland C, Bagheri S, Witte S, et al. 
Acupuncture treatment in irritable bowel syndrome. Gut. 2006;55(5):649–54.  
154.  Dhond RP, Yeh C, Park K, Kettner N, Napadow V. Acupuncture modulates 
resting state connectivity in default and sensorimotor brain networks. Pain. 
2008;136(3):407–18.  
155.  Ren Y, Bai L, Feng Y, Tian J, Li K. Investigation of acupoint specificity by 
functional connectivity analysis based on graph theory. Neurosci Lett. 
2010;482(2):95–100.  
156.  Songzi W, Lu R, Lianqun J, Zhongyue G, Xu F, Wenna C, et al. Effect of 
acupuncture at Neiguan ( PC 6 ) on cardiac function using echocardiography in 
myocardial ischemia rats induced by isoproter-enol. J Tradit Chinese Med. 
2015;35(6):653–8.  
157.  Zatorre RJ, Jones-Gotman M, Evans  a C, Meyer E. Functional localization and 
lateralization of human olfactory cortex. Nature. 1992;360(6402):339–40.  
158.  Urasaki E, Wada S, Yasukouchi H, Yokota A. Effect of transcutaneous electrical 
nerve stimulation ( TENS ) on central nervous system amplification of 
somatosensory input. J Neurol. 1998;245:143–8.  
159.  Ferretti A, Babiloni C, Arienzo D, Del Gratta C, Rossini PM, Tartaro A, et al. 
Cortical brain responses during passive nonpainful median nerve stimulation at 
low frequencies (0.5-4 Hz): An fMRI study. Hum Brain Mapp. 2007;28(7):645–
53.  
160.  Tada H, Fujita M, Harris M, Tatewaki M. Neural Mechanism of Acupuncture-
Induced Gastric Relaxations in Rats. Dig Dis Sci. 2003;48(1):59–68.  
161.  Zhishun W, Liwei Q, Tatsuyuki U, Jiande C. Mechanisms of various gastric 
electrical stimulations. Gastroenterology. 2000;118(4):A669.  
162.  Andrews PLR. Physiology of Nausea and Vomiting. Br J Anaesth. 
1992;69(Suppl. 1):2S–19S.  
163.  Imai K, Ariga H, Chen C, Mantyh C, Pappas TN, Takahashi T. Effects of 
electroacupuncture on gastric motility and heart rate variability in conscious rats. 
Auton Neurosci Basic Clin. 2008;138(1–2):91–8.  
164.  Colin‐Jones DG, Himsworth RL. The location of the chemoreceptor controlling 
gastric acid secretion during hypoglycaemia. J Physiol. 1970;206(2):397–409.  
165.  Davison JS. Response of single vagal afferent fibres to mechanical and chemical 




166.  Gwyn DG, Leslie RA, Hopkins DA. Gastric afferents to the nucleus of the 
solitary tract in the cat. Neurosci Lett. 1979;14(1):13–7.  
167.  Kalia M, Mesulam M. Brain stem projections of sensory and motor components 
of the vagus complex in the cat: II. Laryngeal, tracheobronchial, pulmonary, 
cardiac, and gastrointestinal branches. J Comp Neurol. 1980;193(2):467–508.  
168.  Guan YH, Wu XP. The influence of electroacupunturing Neiguan on the content 
of ET, TXB2, and 6-Keto-PGF1a in acute myocardial ischemia rabbits. Hu Bei 
Zhong Yi Xue Yuan Xue Bao. 2005;7(2):13–4.  
169.  Zhang FB, Zhou YP, Wang YL, Wang KM. Effect of electroacupuncture on 
blood free radicals, ET and CGRP contents in rats with acute myocardial 
ischemia. Acupunct Res. 2002;27(3):192–6.  
170.  Peuker ET, Filler TJ. The nerve supply of the human auricle. Clin Anat. 
2002;15(1):35–7.  
171.  Schuknecht HF. Pathology of the ear. Cambridge: Harvard University; 1974.  
172.  Lang J. Clinical anatomy of the head: Neurocranium. Orbit, Craniocervical Reg 
Berlin Springer-Verlag. 1983;186–203.  
173.  Mulazimoglu S, Flury R, Kapila S, Linder T. Effects of a sensory branch to the 
posterior external ear canal : coughing , pain , Ramsay Hunt ’ s syndrome and 
Hitselberger ’ s sign. J Laryngol Otol. 2017;131(1):329–33.  
174.  Alvord LS, Farmer BL. Anatomy and orientation of the human external ear. 
Journal-American Acad Audiol. 1997;8:383–90.  
175.  English GM. Otolaryngology. New York: Harper and Row; 1976.  
176.  Lucente FE. Anatomy, History and physiology. In: W S, editor. The External 
Ear. Philadelphia; 1995. p. 1–17.  
177.  Cakmak YO, Apaydin H, Kiziltan G, Gündüz A, Ozsoy B, Olcer S, et al. Rapid 
Alleviation of Parkinson’s Disease Symptoms via Electrostimulation of Intrinsic 
Auricular Muscle Zones. Front Hum Neurosci. 2017;11(June):1–16.  
178.  Gao XY, Rong P, Ben H, Liu K, Zhu B, Zhang S. Morphological and 
electrophysiological characterization of auricular branch of vagus nerve: 
Projections to the NTS in mediating cardiovascular inhibition evoked by the 
acupuncture-like stimulation. Abstr Soc Neurosci. 2010;694:22.  
179.  Kraus T, Hosl K, Kiess O, Schanze A, Kornhuber J, Forster C. BOLD fMRI 
deactivation of limbic and temporal brain structures and mood enhancing effect 
by transcutaneous vagus nerve stimulation. J Neural Transm. 
2007;114(11):1485–93.  
180.  Kraus T, Kiess O, Hosl K, Terekhin P, Kornhuber J, Forster C. CNS BOLD 
fMRI effects of sham-controlled transcutaneous electrical nerve stimulation in 
the left outer auditory canal–a pilot study. Brain Stimul. 2013;6(5):798–804.  
181.  Dietrich S, Smith J, Scherzinger C, Hofmann-Preiß K, Freitag T, Eisenkolb A, et 
al. A novel transcutaneous vagus nerve stimulation leads to brainstem and 
cerebral activations measured by functional MRI. Biomed Tech. 2008;53:104–
11.  
182.  Lanska DJ. JL Corning and vagal nerve stimulation for seizures in the 1880s. 
81 
 
Neurology. 2002;58(3):452–9.  
183.  Zabara J. Inhibition of experimental seizures in canines by repetitive vagal 
stimulation. Epilepsia. 1992;33(6):1005–12.  
184.  Ng M, Devinsky O. Vagus nerve stimulation for refractory idiopathic generalised 
epilepsy. Seizure. 2004;13(3):176–8.  
185.  Schachter SC, Wheless JW. The evolving place of vagus nerve stimulation 
therapy. Neurology. 2002;59(6 suppl 4):S1–2.  
186.  Howland RH. New Developments with Vagus Nerve Stimulation Therapy. J 
Psychosoc Nurs. 2014;52(3):175–82.  
187.  Ellrich J. Transcutaneous vagus nerve stimulation. Eur Neurol Rev. 
2011;6(4):254–6.  
188.  Grazzi L, Corsini E, Ciusani E, Usai S, Vasco C, Bussone G. Evaluation of 
immune parameters in chronic migraine with medication overuse. Neurol Sci. 
2014;35(SUPPL. 1):171–3.  
189.  Dedeurwaerdere S, Cornelissen B, Van Laere K, Vonck K, Achten E, Slegers G, 
et al. Small animal positron emission tomography during vagus nerve stimulation 
in rats: a pilot study. Epilepsy Res. 2005;67(3):133–41.  
190.  Saper CB, Kibbe MR, Hurley KM, Spencer S, Holmes HR, Leahy KM, et al. 
Brain Natriuretic Peptidelike Immunoreactive Innervation of the Cardiovascular 
and Cerebrovascular Systems in the Rat. Circ Res. 1990;67(6):1345–54.  
191.  Iriarte J, Urrestarazu E, Alegre M, MacÍas A, Gómez A, Amaro P, et al. Late-
onset periodic asystolia during vagus nerve stimulation. Epilepsia. 
2009;50(4):928–32.  
192.  Fahy BG. Intraoperative and perioperative complications with a vagus nerve 
stimulation device. J Clin Anesth. 2010;22(3):213–22. 
193.  Marzec M, Edwards J, Sagher O, Fromes G, Malow BA. Effects of vagus nerve 
stimulation on sleep-related breathing in epilepsy patients. Epilepsia. 
2003;44(7):930–5.  
194.  Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma 
ES, et al. Vagus nerve stimulation therapy for partial-onset seizures: A 
randomized active-control trial. Neurology. 1998;51(1):48–55.  
195.  Nomura S, Mizuno N. Central distribution of primary afferent fibres in the 
Arnold’s nerve (the auricular branch of the vagus nerve): a transganglionic HRP 
study in the cat. Brain Res. 1984;292:195–205.  
196.  Ruggiero, D. A., Underwood, M. D., Mann, J. J., Anwar, M., & Arango V. The 
human nucleus of the solitary tract: visceral pathways revealed with an “in vitro” 
postmortem tracing method. J Auton Nerv Syst. 2000;79:181–90.  
197.  Sawchenko PE. Central connections of the sensory and motor nuclei of the vagus 
nerve. J Auton Nerv Syst. 1983;9(1):13–26.  
198.  Ozaki Y, Genkawa T, Futami Y. Near-Infrared Spectroscopy. 3rd ed. 
Encyclopedia of Spectroscopy and Spectrometry. Elsevier Ltd.; 2017. 40-49 p.  
199.  Jue T, Masuda K. Application of Near Infrared Spectroscopy in Biomedicine. 4th 
82 
 
Editio. New York: Springer; 2013. 1-21, 59-75 p.  
200.  Siesler HW, Ozaki Y, Kawata S, Heise HM. Near-infrared spectroscopy: 
principles, instruments, applications. John Wiley & Sons; 2008. 75-112 p.  
201.  Fulham MJ. Neuroimaging. In: Encyclopedia of Neuroscience. NSW (Australia): 
Elsevier Inc.; 2004. p. 459–70.  
202.  Nicolai L. Über Sichtbarmachung, Verlauf und chemische Kinetik der 
Oxyhämoglobinreduktion im lebenden Gewebe, besonders in der menschlichen 
Haut. Pflügers Arch Eur J Physiol. 1932;229(1):372–84.  
203.  Millikan GA. The oximeter, an instrument for measuring continuously oxygen 
saturation of arterial blood in man. Rev Sci Instrum. 1942;(13):434–444.  
204.  Wood EH, Geraci JE. Photoelectric determination of arterial oxygen saturation in 
man. J Lab Clin Invest. 1949;34:387–401.  
205.  Brazy JE, Lewis D V, Mitnick MH, Jobsis FF. Noninvasive monitoring of 
cerebral oxygenation in preterm infants. Pediatrics. 1985;75:217–225.  
206.  Chance B, Nioka S, Kent J, McCully K, Fountai M, Greenfeld R. Time-resolved 
spectroscopy of hemoglobin and myoglobin in resting and ischemic muscle. Anal 
Biochem. 1988;174:698–707.  
207.  Ferrari M, Giannini I, Sideri G, Zanette E. Continuous noninvasive monitoring of 
human brain by near infrared spectroscopy. Adv Exp Med Biol. 1985;191:873–
882.  
208.  Tamura M, Haezki O, Nioka S, Chance B, Smith DS. The simultaneous 
measurements of tissue oxygen concentration and energy state by near-infrared 
and nuclear magnetic resonance spectroscopy. Adv Exp Med Biol. 
1988;222:359–363.  
209.  Harada H, Eura Y, Shiraishi K, Kato T, Soda T. Coherence analysis of EEG 
changes during olfactory stimulation. Clin Electroencephalogr. 1998;29:96–100.  
210.  Klemm WR, Lutes SD, Hendrix D V, Warrenburg S. Topographical EEG maps 
of human responses to odors. Chem Senses. Chem Senses. 1992;17:347–61.  
211.  Martin GN. Human electroencephalographic (EEG) response to olfactory 
stimulation: two experiments using the aroma of food. Int J Psychophysiol. 
1998;30:287–302.  
212.  Cho H, Nemeto EM, Yonas H, Balzer J, Sclabassi RJ. Cerebral monitoring by 
means of oximetry and somatosensory evoked potentials during carotid 
endarterectomy. J Neurosurg. 1998;89:533–8.  
213.  Edmonds HL, Singer I, Sehic A, Strickland TJ. Multimodality Neuromonitoring 
for Neurocardiology. Vol. 11, Journal of Intervention Cardiology. 1998. p. 197–
204.  
214.  Hongo, K., Kobayashi, S., Okudera, H., Hokama, M., & Nakagawa F. 
Noninvasive cerebral optical spectroscopy: depth-resolved measurements of 
cerebral haemodynamics using indocyanine green. Neurol Res. 1995;17(2):89–
93.  
215.  Levy LM, Henkin RI, Hutter A, Lin CS, Martins D, Schellinger D. Functional 
MRI of human olfaction. J Comput Assist Tomogr. 1997;21(6):849–56.  
83 
 
216.  Motokizawa F, Furuya N. Neural pathway associated with the EEG arousal 
response by olfactory stimulation. Clin Neurophysiol. 1973;35(1):83–91.  
217.  Rolls T, Baylis L. Gustatory , Olfactory , Orbitofrontal Cortex and Visual 
Convergence within the Primate. J Neurosci. 1994;14(9):5437–52.  
218.  Royet JP, Hudry J, Zald DH, Godinot D, Gre MC. Functional Neuroanatomy of 
Different Olfactory Judgments. Neuroimage. 2001;13:506–19.  
219.  Sobel N, Prabhakaran V, Desmond JE, Glover GH, Sullivan E V, Gabrieli JDE. 
A method for functional magnetic resonance imaging of olfaction. J Neurosci 
Methods. 1997;78:115–23.  
220.  Sobel N, Prabhakaran V, Desmond JE, Glover GH, Goode RL, Sillivan E V, et 
al. Sniffing and smelling: Separate subsystems in the human olfactory cortex. 
Nature. 1998;392(6673):282–7.  
221.  Yousem DM, Williams SC, Howard RO, Andrew C, Simmons A, Allin M, et al. 
Functional MR imaging during odor stimulation: preliminary data. Radiology. 
1997;204(3):833–8.  
222.  Ghasemi A, Zahediasl S. Normality tests for statistical analysis: A guide for non-
statisticians. Int J Endocrinol Metab. 2012;10(2):486–9.  
223.  Gibbons JD, Chakraborti S. Nonparametric statistical inference. In: International 
encyclopedia of statistical science. Berlin Heidelberg: Springer; 2011. p. 977–9.  
224.  Taheri SM, Hesamian G. A generalization of the Wilcoxon signed-rank test and 
its applications. Stat Pap. 2013;54(2):457–70.  
225.  McCrum-Gardner. Which is the correct statistical test to use? Br J Oral 
Maxillofac Surg. 2008;46:38–41.  
226.  Murkin JM, Adams SJ, J NR, Quantz M, Bainbridge D, Iglesias I, et al. 
Monitoring brain oxygen saturation during coronary bypass surgery: a 
randomized, prospective study. Anesth Analg. 2007;104(1):51–8.  
227.  Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A 
novel augmentation strategy for treating resistant major depression. Am J 
Psychiatry. 2001;158(1):131–4.  
228.  Bland JM, Altman DG. Multiple significance tests: The Bonferroni method. 
BMJ. 1995;310(6973):170.  
229.  Ehrenstein WH, Ehrenstein A. Psychophysical Methods. Mod Tech Neurosci Res 
. 1999;1211–41.  
230.  Doty RL. The odor Discrimination/Memory TestTM Administration Manual. 2nd 
Editio. Haddon Heights, New Jersey: Sensonics, Inc.; 2003. 1-11 p.  
231.  Covidien. Operations Manual INVOS System, Model 5100C. 2013;43–67. 232. 
  
232.    Edmonds  Jr. HL, Ganzel BL, Austin  3rd EH. Cerebral oximetry for cardiac and 
vascular surgery. Semin Cardiothorac Vasc Anesth. 2004;8(2):147–66.  
233.  Higami T, Kozawa S, Asada T, Obo H, Gan K, Iwahashi K, et al. Retrograde 
cerebral perfusion versus selective cerebral perfusion as evaluated by cerebral 




234.  Roberts KW, CrnKowic AP, Linneman LJ. Near-infrared spectroscopy detects 
critical cerebral hypoxia during carotid endarterectomy in awake patients. 
Anesthesiology. 1998;9:A933.  
235.  Singer I, Dawn B, Edmonds H, Stickland TJ. Syncope is predicted by 
neuromonitoring in patients with ICDs. Pacing Clin Electrophysiol. 
1999;22(1):216–22.  
236.  Yao FSF, Tseng CC, Woo D, Huang SW, Levin SK. Maintaining cerebral 
oxygen saturation during cardiac surgery decreased neurological complications. 
Anesthesiology. 2001;95:A152.  
237.  Alexander JC, Knonenfeld MA, Dance GR. Reduced Postoperative Length of 
Stay May Result From Using Cerebral Oximetry Monitoring to Guide Treatment. 
Annu Thorac Surg. 2002;73(1):s373.  
238.  Iglesias I, Murkin JM, Bainbridge D, Adams S. Monitoring cerebral oxygen 
saturation significantly decreases postoperative length of stay: a prospective 
randomized blinded study. Hear Surg Forum. 2003;6:204.  
239.  Damian MS, Schlosser R. Bilateral near infrared spectroscopy in space-
occupying middle cerebral artery stroke. Neurocrit Care. 2007;6(3):165–73.  
240.  Misra M, Stark J, Dujovny M, Widman R, Ausman JI. Transcranial cerebral 
oximetry in random normal subjects. Neurol Res. 1998;20(2):137–41.  
241.  Orihuela-Espina F, Leff DR, James DRC, Darzi AW, Yang GZ. Quality control 
and assurance in functional near infrared spectroscopy (fNIRS) experimentation. 
Phys Med Biol. 2010;55(13):3701–24.  
242.  Hessel TW, Hyttel-Sorensen S, Greisen G. Cerebral oxygenation after birth–a 
comparison of INVOS® and FORE‐SIGHTTM near‐infrared spectroscopy 
oximeters. Acta Paediatr. 2014;103(5):488–93.  
243.  Thavasothy M, Broadhead M, Elwell C, Peters M, Smith M. A comparison of 
cerebral oxygenation as measured by the NIRO 300 and the INVOS 5100 near-
infrared spectrophotometers. Anaesthesia. 2002;57(10):999–1006.  
244.  Maharjan A, Wang E, Peng M, Cakmak YO. Improvement of Olfactory Function 
With High Frequency Non-invasive Auricular Electrostimulation in Healthy 
Humans. Front Neurosci. 2018;12(Article 225 (Provisionally accepted; awaiting 
publication)):1–14.  
245.  Choudhury ES, Moberg P, Doty RL. Influences of Age and Sex on a 
Microencapsulated Odor Memory Test. Chem Senses. 2003;28:799–805.  
246.  Ziomber A, Thor P, Krygowska-Wajs A, Zalecki T, Moskala M, Romanska I, et 
al. Chronic impairment of the vagus nerve function leads to inhibition of 
dopamine but not serotonin neurons in rat brain structures. Pharmacol reports. 
2012;64(6):1359–67.  
247.  Cakmak YO, Akpinar IN, Ekinci G, Bekiroglu N. Point- and frequency-specific 
response of the testicular artery to abdominal electroacupuncture in humans. 
Fertil Steril. 2008;90(5):1732–8.  
248.  Cakmak YO, Akpinar IN, Yoldemir T. Decreasing the Uterine Blood Flow with 
85 
 
Electroacupuncture: Bidermatomal and Monodermatomal Applications. Gynecol 
Obstet Invest. 2016;82(2):151–6.  
249.  Zhao ZQ. Neural mechanism underlying acupuncture analgesia. Prog Neurobiol. 
2008;85(4):355–75.  
250.  Mayer EA. Gut feelings: the emerging biology of gut–brain communication. Nat 
Rev Neurosci. 2011;12(8):1–30.  
251.  Rolls ET, Rolls JH. Olfactory Sensory-Specific Satiety in Humans. Physiology. 
1997;61(3):461–73.  
252.  Gottfried JA, Winston JS, Dolan RJ. Dissociable codes of odor quality and 
odorant structure in human piriform cortex. Neuron. 2006;49(3):467–79.  
253.  Wise PM, Olsson MJ, Cain WS. Quantification of odor quality. Chem Senses. 
2000;25(4):429–43.  
254.  Doty RL, Riklan M, Deems DA, Reynolds C, Stellar S. The olfactory and 
cognitive deficits of Parkinson’s disease: evidence for independence. Ann 
Neurol. 1989;25(2):166–71.  
255.  Shute CCD, Lewis PR. The Ascending Cholinergic Reticular System : 
Neocortical , Olfactory And subcortical projections. Brain. 1967;90(3):497–520.  
256.  Gervais R. Unilateral lesions of the olfactory tubercle modifying general arousal 
effects in the rat olfactory bulb. Electroencephalogr Clin Neurophysiol. 
1979;46(6):665–74.  
257.  Wesson, D. W., & Wilson DA. Sniffing out the contributions of the olfactory 
tubercle to the sense of smell: hedonics, sensory integration, and more? Neurosci 
Biobehav Rev. 2011;35(1):655–68.  
258.  Solano-Flores LP, Aguilar-Baturoni HU, Guevara-Aguilar R. Locus coeruleus 
influences upon the olfactory tubercle. Brain Res Bull. 1980;5:383–9.  
259.  Guevara-Guzman R, Garcia-Diaz DE, Solano-Flores LP, Wayner MJ, Armstrong 
DL. Role of the paraventricular nucleus in the projection from the nucleus of the 
solitary tract to the olfactory bulb. Brain Res Bull. 1991;27(3–4):447–50.  
260.  Pierce ET, Foote WE, Hobson JA. The efferent connection of the nucleus raphe 
dorsalis. Brain Res. 1976;107:137–44.  
261.  Hervé D, Pickel VM, Joh TH, Beaudet A. Serotonin axon terminals in the ventral 
tegmental area of the rat: fine structure and synaptic input to dopaminergic 
neurons. Brain Res. 1987;435(1–2):71–83.  
262.  Chandler DJ, Gao W-J, Waterhouse BD. Heterogeneous organization of the locus 
coeruleus projections to prefrontal and motor cortices. Proc Natl Acad Sci . 
2014;111(18):6816–21.  
263.  Mello-Carpes PB, Izquierdo I. The nucleus of the solitary tract→nucleus 
paragigantocellularis→locus coeruleus→CA1 region of dorsal hippocampus 
pathway is important for consolidation of object recognition memory. Neurobiol 
Learn Mem. 2013;100:56–63.  
264.  Mooney KE, Inokuchi A, Snow  Jr. JB, Kimmelman CP. Projections from the 
ventral tegmental area to the olfactory tubercle in the rat. Otolaryngol Head Neck 
Surg . 1987;96(2):151–7.  
86 
 
265.  Kannan H, Yamashita H. Connections of neurons in the region of the nucleus 
tractus solitarius with the hypothalamic paraventricular nucleus: Their possible 
involvement in neural control of the cardiovascular system in rats. Brain Res. 
1985;329(1–2):205–12.  
266.  Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral 
midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev. 
2007;56(1):27–78.  
267.  Price JL. Olfactory Higher Centers Anatomy. 2010. 129-136 p.  
268.  Zhou J, Jia C, Feng Q, Bao J, Luo M. Prospective Coding of Dorsal Raphe 
Reward Signals by the Orbitofrontal Cortex. J Neurosci. 2015;35(6):2717–30.  
269.  Samuels E, Szabadi E. Functional Neuroanatomy of the Noradrenergic Locus 
Coeruleus: Its Roles in the Regulation of Arousal and Autonomic Function Part I: 
Principles of Functional Organisation. Curr Neuropharmacol. 2008;6(3):235–53.  
270.  Escanilla OD, Victor JD, Di Lorenzo PM. Odor-Taste Convergence in the 
Nucleus of the Solitary Tract of the Awake Freely Licking Rat. J Neurosci. 
2015;35(16):6284–97.  
271.  Cobo JL, Solé-Magdalena A, Menéndez I, de Vicente JC, Vega JA. Connections 
between the facial and trigeminal nerves: Anatomical basis for facial muscle 
proprioception. JPRAS Open. 2017;12:9–18.  
272.  van der Kooy D, Koda LY, McGinty JF, Gerfen CR, Bloom FE. The 
organization of projections from the cortex, amygdala, and hypothalamus to the 
nucleus of the solitary tract in rat. J Comp Neurol. 1984;224(1):1–24.  
273.  Del Gratta C, Della Penna S, Ferretti A, Franciotti R, Pizzella V, Tartaro A, et al. 
Topographic Organization of the Human Primary and Secondary Somatosensory 
Cortices: Comparison of fMRI and MEG Findings. Neuroimage. 2002;17:1373–
83.  
274.  Schobel SA, Buxton RB. A pathophysiological framework of hippocampal 
dysfunction in ageing and disease. Nat Rev Neurosci. 2011;12:585–601.  
275.  Moyse E, Bauer S, Charrier C, Coronas V, Krantic S, Jean A. Neurogenesis and 
neural stem cells in the dorsal vagal complex of adult rat brain: new vistas about 
autonomic regulations- a review. Auton Neurosci. 2006;50(8):126–7.  
276.  Woolsey TA, Hanaway J, Mokhtar HG. The brain atlas; a visual guide to the 
human central nervous system. 2nd editio. USA: JohnWiley & Sons; 2003.  
277.  Yang H, Wu S, Zheng Q, Xiao C, Liu X, Xiao Y, et al. Meta-analysis on 
protective effect of electroacupuncture at “Neiguan” (PC 6) in rats with 
reperfusion injury induced myocardial ischemia. World J Acupuncture-
Moxibustion. 2015;25(3):43–53.  
278.  Travagli RA, Hermann GE, Browning KN, Rogers RC. NIH Public Access. 
Annu Rev Physio. 2011;68(7):279–305.  
279.  Hayakawa T, Takanga A, Tanaka K, Maeda S, Seki M. Organization and 
distribution of the upper and lower esophageal motoneurons in the medulla and 
the spinal cord of the rat. Okajimas Folia Anat Jpn. 2002;78(6):263–79.  
280.  Norgren R, Smith GP. Central distribution of subdiaphragmatic vagal branches in 
87 
 
the rat. J Comp Neurol. 1988;273(2):207–23.  
281.  Augustine JR. Circuitry and fimctional aspects of the insular lobe in primates 
including humans. Brain Res Rev. 1996;22:229–44.  
282.  Shepherd GM. 16 New Perspectives on Olfactory Processing and Human Smell. 
Neurobiol olfaction. 2009;395–403.  
283.  Zald D, Pardo J. Emotion, olfaction, and the human amygdala: amygdala 
activation during aversive olfactory stimulation. Proc Natl Acad Sci. 
1997;94(8):4119–24.  
284.  Jones-Gotman M, Zatorre RJ. Odor recognition memory in humans role of right 
temporal and orbitofrontal regions. Brain Cogn. 1993;22:182–98.  
285.  Hummel T, Pauli E, Schuler P, Kettenmann B, Stefan H, Kobal G. 
Chemosensory event-related potentials in patients with temporal lobe epilepsy. 
Epilepsia. 1995;36(1):79–85.  
286.  Bohning DE, Lomarev MP, Denslow S, Nahas Z, George MS, Shastri A, et al. 
Feasibility of vagus nerve stimulation – Synchronized blood oxygenation level – 
Dependent functional MRI. Invest Radiol. 2001;36(8):470–9.  
287.  Henry, T. R., Votaw, J. R., Pennell, P. B., Epstein, C. M., Bakay, R. A. E., Faber 
T et al. Acute blood flow changes and efficacy of vagus nerve stimulation in 
partial epilepsy. Neurology. 1999;52(6):1166–1166.  
288.  Henry TR, Bakay R a, Votaw JR, Pennell PB, Epstein CM, Faber TL, et al. Brain 
blood flow alterations induced by therapeutic vagus nerve stimulation in partial 
epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia. 
1998;39(9):983–90.  
289.  Lomarev M, Denslow S, Nahas Z, Chae J-H, George MS, E BD. vagus nerve 
stimulation synchronized BOLD fMRI suggests that VNS in depressed adult has 
frequency and/or dose dependent effects. J Psychiatr Res. 2002;36:219–27.  
290.  Puce A, Constable T, Luby ML, McCarthy G, Nobre AC, Spencer DD, et al. 
Functional magnetic resonance imaging of sensory and motor cortex: comparison 
with electrophysiological localization. J Neurosurg. 1995;83:262–70.  
291.  Gyngell ML, Bock C, Schmitz B, Hoehn-Berlage M, Hossmann KA. Variation of 
functional MRI signal in response to frequency of somatosensory stimulation in 
alpha-chloralose anesthetized rats. Magn Reson Med. 1996;36(13–15).  
292.  Ibanez V, Deiber MP, Sadato N, Toro C, Grissom J, Woods RP, et al. Effects of 
stimulus rate on regional cerebral blood flow after median nerve stimulation. 
Brain. 1995;118:1339–51.  
293.  Jones BP, Moskowitz HR, Butters N. Olfactory discrimination in alcoholic 
Korsakoff patients. Neuropsychologia. 1975;13(2):173–9.  
294.  Mair RG, L DR, Kelly KM, Wilson CS, Langlais PJ, McEntee WJ, et al. 
Multimodal Sensory Discrimination Korsakoff ’ S Psychosis * Deficits. 
Neuropsychologia. 1986;24(6):831–9.  
295.  Sajjadian A, Doty RL, Gutnick DN, Chirurgi RJ, Sivak M, Perl D. Olfactory 




296.  Naudin M, Atanasova B. Neuroscience and Biobehavioral Reviews Olfactory 
markers of depression and Alzheimer ’ s disease. Neurosci Biobehav Rev. 
2014;45:262–70. 
297.  Slow EJ, Postuma RB, Lang AE. Implications of nocturnal symptoms towards 
the early diagnosis of Parkinson ’ s disease. J Neural Transm. 2014;121(1):49–
57.  
298.  Wu KN, Tan BK, Howard JD, Conley DB, Gottfried JA. Olfactory input is 
critical for sustaining odor quality codes in human orbitofrontal cortex. Nat 
Neurosci. 2012;15(9):1313–9.  
299.  Cohen J. Statistical power analysis for the behavioral sciences. 2nd Editio. 1988.  
300.  Ferdenzi C, Schirmer A, Roberts SC, Delplanque S, Porcherot C, Cayeux I, et al. 
Affective dimensions of odor perception: A comparison between swiss, British, 
and singaporean populations. Emotion. 2011;11(5):1168–81.  
301.  Chrea C, Valentin D, Abdié H. Graded structure in odour categories: A cross-
cultural case study. Perception. 2009;38(2):292–309.  
302.  Ayabe-Kanamura S, Schicker I, Laska M, Hudson R, Distel H, Kobayakawa T, et 
al. Differences in perception of everyday odors: a Japanese-German cross- 





























Inclusion to study Screening form: 
Participant ID:  
Age:  
 
Please tick in the boxes below to show that you are eligible to participate in the study: 
☐ Are you a male?  
☐ Is your ethinicity NZ European (Kiwi-Pakeha)?  
☐ Are all four of your grandparents are NZ Europeans as well? 
☐ Are you in good health? (no signs of flu, fever, diarrheoa or any sort of illness) 
☐ Are you a non-smoker? 
 
Are you on any medication? 
☐ Yes     ☐ No 
 
Do you have any allergies? 
☐ Yes     ☐ No 
 
Do you have any sorts of disorders or diseases?  
☐ Yes     ☐ No 
 
Have you had any of disorders or diseases before? 
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